UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☒	~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

For the quarterly period ended ~~September~~June 30, ~~2020~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐	~~TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

For the transition period from to

Commission File Number: 001-39059

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

85-1021707

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

28159 Avenue Stanford

Suite 220

Valencia, CA91355

(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code: (661)367-9170

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

RCEL

The ~~NASDAQ~~Nasdaq Stock Market LLC

~~Securities registered pursuant to section 12(g) of the Act:~~

~~None~~

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has selected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s ~~$0.0001~~common stock, par value ~~common stock~~$0.0001, outstanding as of ~~November 6, 2020~~August 2, 2023 was ~~21,623,287~~25,478,301

TABLE OF CONTENTS


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENT			3

PART I – FINANCIAL INFORMATION				3
			5
~~Item 1.~~		~~Financial Statements~~			3
Item 1.	Financial Statements		5

	Consolidated Balance Sheets – ~~September 30, 2020 and~~ June 30, ~~2020 (Unaudited)~~2023 (unaudited) and December 31, 2022			3	5

		Consolidated Statements of Operations for the ~~three~~three-months and ~~six months~~six-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019 (Unaudited)~~2022 (unaudited)			4	6

		Consolidated Statements of Comprehensive Loss for the ~~three months~~three-months and six-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019 (Unaudited)~~2022 (unaudited)			5	7

		Consolidated Statements of Stockholders’ Equity for the ~~three months~~three-months and six-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019 (Unaudited)~~2022 (unaudited)			6	8

		Consolidated Statements of Cash Flows for the ~~six months~~six-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019 (Unaudited)~~2022 (unaudited)			7

		~~Notes to Financial Statements~~			8
			10

	Notes to Consolidated Financial Statements (unaudited)		11

Item 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations			19
			32

Item 3.		Quantitative and Qualitative Disclosures About Market Risk			23
			37

Item 4.		Controls and Procedures			23	37

Part II – OTHER INFORMATION				24
			38
~~Item 1.~~		~~Legal Proceedings~~			24

Item ~~1A.~~1.	Legal Proceedings	~~Risk Factors~~			24
			38

Item 1A	Risk Factors		38

Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds			24
			39

Item 3.		Defaults Upon Senior Securities			24
			39

Item 4.		Mine Safety Disclosures			24
			39
~~Item 5.~~		~~Other Information~~			24

Item 6.5.	Other Information	~~Exhibits~~			24	39

Item 6.	Exhibits		40

Signatures				25	41

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

~~FORWARD-LOOKING STATEMENT~~

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future ~~results~~revenues; solvency; future industry market conditions; future changes in our capacity and operations; future operating and overhead costs; intellectual property; regulatory and related approvals; the conduct or outcome of ~~operations~~pre-clinical or clinical (human) studies; operational and management restructuring activities (including implementation of methodologies and changes in the board of directors); our ability to expand our sales organization to address effectively existing and new markets that we intend to target; future employment and contributions of personnel; tax and rising interest rates; productivity, business process, rationalization, investment, acquisition and acquisition integrations, consulting, operational, tax, financial ~~position,~~and capital projects and initiatives; inflationary pressures on the ~~anticipated impact of~~U.S. and global economy; changes in the ~~novel coronavirus,~~legal or COVID-19, pandemic on our business, business strategy, prospective products, product approvals, research and development costs, anticipated timing and likelihood of success of clinical trials, expected timing of the release of clinical trial data, the plans and objectives of management for future operationsregulatory environment; and future ~~results of anticipated products, are forward-looking statements.~~working capital, costs, revenues, business opportunities, cash flows, margins, earnings and growth. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,”~~“anticipate,~~ “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, or “continue” or the negative of these terms or other similar expressions.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the sections in this Quarterly Report on Form 10-Q titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for our management to predict all risk factors and uncertainties.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Stockholders
AVITA Medical, Inc.

Results of review of interim financial statements

We have reviewed the accompanying Consolidated Balance Sheet of AVITA Medical, Inc. (a Delaware corporation) and subsidiaries (the “Company”) as of June 30, 2023 and the related Consolidated Statements of Operations, Comprehensive Loss, and Stockholders’ Equity for the three-month and six-month periods ended June 30, 2023 and 2022, Cash Flows for the six-month periods ended June 30, 2023 and 2022, and the related notes (collectively referred to as the “interim financial statements”). Based on our reviews, we are not aware of any material modifications that should be made to the accompanying interim financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Consolidated Balance Sheet of the Company as of December 31, 2022, and the related Consolidated Statements of Operations, Comprehensive Loss, Stockholders’ Equity, and Cash Flows for the year then ended (not presented herein); and in our report dated February 23, 2023, we expressed an unqualified opinion on those Consolidated Financial Statements. In our opinion, the information set forth in the accompanying Consolidated Balance Sheet as of December 31, 2022, is fairly stated, in all material respects, in relation to the Consolidated Balance Sheet from which it has been derived.

Basis for review results

These interim financial statements are the responsibility of the Company’s management. We are a public accounting firm registered with the PCAOBand are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our reviews in accordance with the standards of the PCAOB. A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

/s/ GRANT THORNTON LLP

Los Angeles, California
August 10, 2023

PART I – Financial Information

Item 1. FINANCIAL STATEMENTS

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

~~Condensed~~ Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)


	As of						As of
	September 30, 2020			June 30, 2020			June 30, 2023			December 31, 2022
ASSETS
Cash	$	65,753		$	73,639
Cash and cash equivalents							$	37,485		$	18,164
Marketable securities								28,562			61,178
Accounts receivable, net		2,360			2,076			5,754			3,515
BARDA receivables		371			356			442			898
Prepaids and other current assets		1,054			990			2,194			1,578
Restricted cash		201			201
Inventory		1,657			1,125			3,058			2,125

Total current assets		71,396			78,387			77,495			87,458
Marketable securities long-term								2,754			6,930
Plant and equipment, net		1,349			1,363			1,598			1,200
Operating lease right-of-use assets		2,216			2,347			1,651			851
Intangible assets		403			364
Other long term assets		55			1

Corporate-owned life insurance asset								2,091			1,238
Intangible assets, net								456			465
Other long-term assets								285			122
Total assets	$	75,419		$	82,462		$	86,330		$	98,264

LIABILITIES AND SHAREHOLDERS’ EQUITY
LIABILITIES, NON-QUALIFIED DEFERRED COMPENSATION PLAN SHARE AWARDS AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	$	3,570		$	4,333			3,837			3,002
Accrued wages and fringe benefits		3,589			2,816			6,200			6,623
Other currrent liabilities		561			560

Current non-qualified deferred compensation liability								2,572			78
Other current liabilities								1,201			990
Total current liabilities		7,720			7,709			13,810			10,693
Non-qualified deferred compensation liability								1,224			1,270
Contract liabilities		435			435			374			698
Operating lease liabilities, long term		1,776			1,917			1,047			306

Total liabilities		9,931			10,061			16,455			12,967

Contingencies (Note 10)
Shareholders’ Equity:
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 21,623,287 and 21,467,912 shares issued and outstanding at September 30, 2020 and June 30, 2020, respectively		3			3
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2020 and June 30, 2020		—			—
Non-qualified deferred compensation plan share awards								1,228			557
Commitments and contingencies (Note 12)
Stockholders' equity:
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 25,447,615 and 25,208,436 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively								3			3
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at June 30, 2023 and December 31, 2022.								-			-
Company common stock held by the non-qualified deferred compensation plan ("NQDC Plan")								(892	)		(127	)
Additional paid-in capital		262,431			259,165			343,769			339,825
Accumulated other comprehensive income		8,194			8,146			7,959			7,627
Accumulated deficit		(205,140	)		(194,913	)		(282,192	)		(262,588	)
Total stockholders' equity								68,647			84,740
Total liabilities, non-qualified deferred compensation plan share awards and stockholders' equity							$	86,330		$	98,264

Total shareholders’ equity		65,488			72,401

Total liabilities and shareholders’ equity	$	75,419		$	82,462

The accompanying notes form part of the ~~consolidated financial statements~~

unaudited Consolidated Financial Statements.

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

~~Condensed~~ Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)


							Three-Months Ended						Six-Months Ended
	Three months ended September 30,						June 30, 2023			June 30, 2022			June 30, 2023			June 30, 2022
	2020			2019
Revenues	$	5,060		$	3,250		$	11,753		$	8,335		$	22,303		$	15,874
Cost of sales		929			619			(2,204	)		(1,386	)		(3,871	)		(3,164	)

Gross profit		4,131			2,631			9,549			6,949			18,432			12,710

BARDA income		596			2,051			530			551			1,157			1,285
Operating expenses:
Sales and marketing expenses		2,935			2,962			(10,003	)		(5,332	)		(16,543	)		(10,160	)
General and administrative expenses		5,536			3,071			(6,165	)		(5,471	)		(14,460	)		(13,005	)
Research and development expenses		3,204			1,635			(5,076	)		(3,059	)		(9,662	)		(6,679	)
Share-based compensation		3,266			672

Total operating expenses		14,941			8,340			(21,244	)		(13,862	)		(40,665	)		(29,844	)

Operating loss		(10,214	)		(3,658	)		(11,165	)		(6,362	)		(21,076	)		(15,849	)
Interest expense		7			11			(7	)		(4	)		(11	)		(4	)
Other income		4			103			801			109			1,526			137

Loss before income taxes		(10,217	)		(3,566	)		(10,371	)		(6,257	)		(19,561	)		(15,716	)
Income tax expense		10			—			(13	)		(4	)		(43	)		(8	)

Net loss	$	(10,227	)	$	(3,566	)	$	(10,384	)	$	(6,261	)	$	(19,604	)	$	(15,724	)

Net loss per common share:
Basic	$	0.48		$	0.19
Diluted	$	0.48		$	0.19

Basic and Diluted							$	(0.41	)	$	(0.25	)	$	(0.78	)	$	(0.63	)
Weighted-average common shares:
Basic		21,503,643			18,719,857
Diluted		21,503,643			18,719,857
Basic and Diluted								25,239,723			24,971,243			25,221,009			24,954,712

The accompanying notes form part of the unaudited ~~condensed consolidated financial statements.~~

Consolidated Financial Statements.

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

~~Condensed~~ Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)


							Three-Months Ended						Six-Months Ended
	Three months ended September 30,						June 30, 2023			June 30, 2022			June 30, 2023			June 30, 2022
	2020			2019
Net loss	$	(10,227	)	$	(3,566	)	$	(10,384	)	$	(6,261	)	$	(19,604	)	$	(15,724	)
Foreign currency translation gain/(loss)		48			(34	)		1			(110	)		(10	)		(92	)

Net unrealized gain/(loss) on marketable securities, net of tax								100			(135	)		342			(432	)
Comprehensive loss	$	(10,179	)	$	(3,600	)	$	(10,283	)	$	(6,506	)	$	(19,272	)	$	(16,248	)

The accompanying notes form part of the unaudited ~~condensed consolidated financial statements.~~

Consolidated Financial Statements.

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

~~Condensed~~ Consolidated Statements of ~~Shareholders’~~Stockholders’ Equity

(In thousands, except shares)

(Unaudited)

   Three Months Ended September 30, 2020
   Common Stock
   Shares    Amount    Additional
Paid-in-
Capital    Accumulated
Other
Comprehensive
Income (Loss)    Accumulated
Deficit Total
Shareholders’
Equity
Balance at June 30, 2020
   21,467,912    $ 3    $ 259,165    $ 8,146    $ (194,913 ) $ 72,401










Net loss
   —      —      —      —      (10,227 ) (10,227 )
Share-based compensation
   —      —      3,266    —      —   3,266
Exercise of stock options
   3,538    —      —      —      —   —
Vesting of restricted stock units
   151,837    —      —      —      —   —
Translation gain
   —      —      —      48    —   48










Balance at September 30, 2020
   21,623,287    $ 3    $ 262,431    $ 8,194    $ (205,140 ) $ 65,488


	Three-Months Ended June 30, 2023
	Common Stock
	Shares		Amount		Company common stock held by the NQDC Plan			Additional Paid-in Capital			Accumulated Other Comprehensive Gain (Loss)		Accumulated Deficit			Total Stockholders' Equity
Balance at March 31, 2023		25,327,761	$	3	$	(892	)	$	342,400		$	7,858	$	(271,808	)	$	77,561
Net loss		-		-		-			-			-		(10,384	)		(10,384	)
Stock-based compensation		-		-		-			1,175			-		-			1,175
Exercise of stock options		114,854		-		-			661			-		-			661
Vesting of restricted stock units		5,000		-		-			-			-		-			-
Change in redemption value of share awards in NQDC plan		-		-		-			(467	)		-		-			(467	)
Other comprehensive gain		-		-		-			-			101		-			101
Balance at June 30, 2023		25,447,615	$	3	$	(892	)	$	343,769		$	7,959	$	(282,192	)	$	68,647

   Three Months Ended September 30, 2019
   Common Stock
   Shares    Amount    Additional
Paid-in-
Capital    Accumulated
Other
Comprehensive
Income (Loss) Accumulated
Deficit Total
Shareholders’
Equity
Balance at June 30, 2019
   18,712,996    $ 3    $ 165,473    $ 8,184 $ (152,828 ) $ 20,832








Net loss
   —      —      —      —   (3,566 ) (3,566 )
Share-based compensation
   —      —      672    —   —   672
Issuance of common stock to director in lieu of directors fees
   15,853    —      107    —   —   107
Beginning balance adjustment related ot the adoption of ASC 842
   —      —      —      —   (55 ) (55 )
Translation loss
   —      —         (34 ) —   (34 )








Balance at September 30, 2019
   18,728,849    $ 3    $ 166,252    $ 8,150 $ (156,449 ) $ 17,956


	Three-Months Ended June 30, 2022
	Common Stock
	Shares		Amount		Company common stock held by the NQDC Plan		Additional Paid-in Capital			Accumulated Other Comprehensive Gain (Loss)			Accumulated Deficit			Total Stockholders' Equity
Balance at March 31, 2022		24,955,581	$	3	$	-	$	335,417		$	7,781		$	(245,386	)	$	97,815
Net loss		-		-		-		-			-			(6,261	)		(6,261	)
Stock-based compensation		-		-		-		1,414			-			-			1,414
Vesting of restricted stock units		47,507		-		-		-			-			-			-
Change in classification of deferred compensation share awards		-		-		-		(192	)		-			-			(192	)
Change in redemption value of share awards in NQDC plan								29									29
Other comprehensive loss		-		-		-		-			(245	)		-			(245	)
Balance at June 30, 2022		25,003,088	$	3	$	-	$	336,668		$	7,536		$	(251,647	)	$	92,560


	Six-Months Ended June 30, 2023
	Common Stock
	Shares		Amount		Company common stock held by the NQDC Plan			Additional Paid-in Capital			Accumulated Other Comprehensive Gain (Loss)		Accumulated Deficit			Total Stockholders' Equity
Balance at December 31, 2022		25,208,436	$	3	$	(127	)	$	339,825		$	7,627	$	(262,588	)	$	84,740
Net loss		-		-		-			-			-		(19,604	)		(19,604	)
Stock-based compensation		-		-		-			3,372			-		-			3,372
Exercise of stock options		146,529		-		-			832			-		-			832
Company common stock held by the NQDC Plan		87,650		-		(765	)		765			-		-			-
Vesting of restricted stock units		5,000		-		-			-			-		-			-
Change in redemption value of share awards in NQDC plan		-		-		-			(1,025	)		-		-			(1,025	)
Other comprehensive gain		-		-		-			-			332		-			332
Balance at June 30, 2023		25,447,615	$	3	$	(892	)	$	343,769		$	7,959	$	(282,192	)	$	68,647


	Six-Months Ended June 30, 2022
	Common Stock
	Shares		Amount		Company common stock held by the NQDC Plan		Additional Paid-in Capital			Accumulated Other Comprehensive Gain (Loss)			Accumulated Deficit			Total Stockholders' Equity
Balance at December 31, 2021		24,925,743	$	3	$	-	$	332,484		$	8,060		$	(235,923	)	$	104,624
Net loss		-		-		-		-			-			(15,724	)		(15,724	)
Stock-based compensation		-		-		-		4,346			-			-			4,346
Exercise of stock options		125		-		-		1			-			-			1
Vesting of restricted stock units		77,220		-		-		-			-			-			-
Change in classification of deferred compensation share awards		-		-		-		(192	)		-			-			(192	)
Change in redemption value of share awards in NQDC plan		-		-		-		29			-			-			29
Other comprehensive loss		-		-		-		-			(524	)		-			(524	)
Balance at June 30, 2022		25,003,088	$	3	$	-	$	336,668		$	7,536		$	(251,647	)	$	92,560

The accompanying notes form part of the unaudited ~~condensed consolidated financial statements.~~

Consolidated Financial Statements.

AVITA ~~Therapeutics,~~Medical, Inc.

~~Condensed~~ Consolidated ~~Statement~~Statements of Cash Flows

(In thousands)

(Unaudited)


	Three Months ended September 30,						Six-Months Ended
	2020			2019			June 30, 2023			June 30, 2022
Cash flow from operating activities:
Net loss	$	(10,227	)	$	(3,566	)	$	(19,604	)	$	(15,724	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		211			66			281			300
Stock-based compensation								3,783			4,346
Non-cash lease expense		131			122			331			341
Loss (gain) on foreign currency transactions		80			(5	)
Provision for write-down of inventories		(77	)		8
Share-based compensation		3,266			672
Issuance of common stock to directors in lieu of directors fees		—			107
Loss on fixed asset disposal								3			-
Patent impairment loss								4			-
Remeasurement and foreign currency transaction (gain)/loss								4			(39	)
Excess and obsolete inventory related charges								68			158
BARDA deferred costs								(64	)		(64	)
Contract cost amortization								170			169
Provision for doubtful accounts								202			10
Amortization of (premium)/discount of marketable securities								(621	)		83
Non-cash changes in the fair value of NQDC plan								937			-
Changes in operating assets and liabilities:
Trade and other receivables		(283	)		(1,915	)		(2,440	)		(777	)
BARDA receivables		(15	)		309			456			(29	)
Prepaids and other current assets		(65	)		268			(295	)		205
Inventory		(453	)		(135	)		(1,003	)		(52	)
Operating lease liability		(127	)		(132	)		(344	)		(349	)
Other long term assets		(54	)		3
Corporate-owned life insurance asset								(681	)		-
Other long-term assets								(164	)		(467	)
Accounts payable and accrued expenses		(860	)		(810	)		747			(179	)
Accrued wages and fringe benefits		765			286			(422	)		(1,178	)
Current non-qualified deferred compensation liability								794			-
Other current liabilities		(5	)		(155	)		229			105
Other long term liabilities		—			(4	)

Non-qualified deferred compensation plan liability								(221	)		-
Contract liabilities								(324	)		(139	)
Other long-term liabilities								-			403
Net cash used in operations		(7,713	)		(4,881	)		(18,174	)		(12,877	)
Cash flows from investing activities:
Cash paid for property and equipment		(209	)		(86	)
Cash paid for patent filing fees		(87	)		(66	)

Net cash used in investing activities		(296	)		(152	)
Purchase of marketable securities								(7,633	)		(32,975	)
Maturities of marketable securities								45,388			25,440
Purchase of plant and equipment								(583	)		(278	)
Patent filing fees								(22	)		(32	)
Net cash provided/(used) in investing activities								37,150			(7,845	)
Cash flow from financing activities:
Principal repayment of finance lease		(4	)		(17	)

Net cash used in financing activities		(4	)		(17	)
Proceeds from exercise of stock options								342			1
Net cash provided by financing activities								342			1
Effect of foreign exchange rate on cash and restricted cash		127			(22	)		3			(52	)
Net decrease in cash and restricted cash		(7,886	)		(5,072	)

Cash and restricted cash at beginning of the period		73,840			20,374

Cash and restricted cash end of the period	$	65,954		$	15,302

Net increase/(decrease) in cash and cash equivalents and restricted cash								19,321			(20,773	)
Cash and cash equivalents and restricted cash beginning of the period								18,164			55,712
Cash and cash equivalents and restricted cash end of the period							$	37,485		$	34,939
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	$	42		$	—
Cash paid for Interest	$	1		$	5
Fixed assets in accounts payable	$	50		$	—
Income taxes paid during the period							$	44		$	17
Interest paid during the period							$	11		$	4
Plant and equipment purchases not yet paid							$	115		$	-
Exercise of stock options not yet paid							$	490		$	-

The accompanying notes form part of the unaudited ~~condensed consolidated financial statements.~~

Consolidated Financial Statements.

AVITA ~~THERAPEUTICS,~~MEDICAL, INC.

Notes to ~~Condensed~~ Consolidated Financial Statements

(Unaudited)

1. The Company

Nature of the Business

~~The~~

AVITA ~~group of companies (comprising AVITA Therapeutics,~~Medical, Inc. (“~~AVITA Therapeutics~~~~” or the “~~~~Company~~”) and its subsidiaries ~~including~~ (collectively, “AVITA Medical ~~Limited (“~~~~AVITA Medical~~~~”)) (collectively, “~~~~AVITA Group~~~~” or “~~we~~”, “~~us”, or “~~our~~Company”), is a ~~commercial-stage~~ regenerative ~~tissue~~medicine company ~~focused on~~leading the ~~treatment~~development and commercialization of ~~burns, trauma~~devices and ~~other acute injuries, together with~~autologous cellular therapies for skin ~~defects like vitiligo.~~restoration. The ~~Company’s lead product is~~Company's RECELL® System technology platform harnesses the ~~RECELL~~^® ~~System,~~regenerative properties of a ~~device that enables healthcare professionals to produce a suspension of~~ ~~Spray-On~~ ~~Skin~~^™ ~~Cells using a small sample of the~~ patient’s own ~~skin.~~skin to create Spray-On Skin™ cells. In September 2018, the United States Food & Drug Administration (“FDA”) granted premarket approval (“PMA”) to the RECELL System for use in the treatment of acute thermal burns in patients eighteen years and older. Following receipt of ~~our~~the original PMA, wethe Company commenced ~~commercializing~~commercialization of the RECELL System in January 2019 in the United States. In ~~addition,~~June 2021, the FDA ~~has granted the Company three Investigational Device Exemptions (“~~~~IDEs~~~~”) studies which have enabled the Company to initiate pivotal clinical investigational studies to seek~~approved expanded ~~FDA (supplementary) PMA~~use of the RECELL System in combination of meshed autografting for ~~each~~acute full-thickness thermal wounds in pediatric and adult patients. In February 2022, the FDA approved a PMA supplement for the RECELL Autologous Cell Harvesting Device, an enhanced ease-of-use device aimed at providing clinicians a more efficient user experience and simplified workflow. On June 7, 2023, the FDA approved a PMA supplement for full-thickness skin defects based on results of the Company's pivotal trial for soft tissue ~~reconstruction, pediatric scalds,~~repair and ~~vitiligo. Enrollment of those clinical studies is ongoing and, if successful, those studies would enable~~reconstruction. Following this approval, the Company commenced a commercial launch on June 8, 2023. On June 16, 2023, the FDA approved a PMA application for the repigmentation of stable depigmented vitiligo lesions. The Company plans to commence ~~commercializing~~a full commercial launch following the expected receipt of in-office reimbursement for the use of RECELL in the physician office setting, which the Company anticipates in 2025. Additionally, on June 29, 2023, the Company submitted a PMA supplement to the FDA for its automated cell disaggregation device, RECELL GO™. RECELL GO maintains the FDA Breakthrough Device designation from predecessor devices.

In February 2019, the Company entered into a collaboration with COSMOTEC Company Ltd ("COSMOTEC"), an M3 Group company, to market and distribute the RECELL System in Japan. Under the ~~United States in each of those indications.~~

~~In March 2020, the World Health Organization declared the outbreak of a novel strain~~terms of the ~~coronavirus (“~~~~COVID-19~~~~”) a pandemic.~~ ~~COVID-19~~ ~~is having,~~agreement, AVITA Medical will supply the RECELL product, and COSMOTEC will ~~likely continue to have, an adverse effect on our business, results~~be the sole distributor of ~~operations, financial condition, and cash flows, and its future impacts remain highly uncertain and unpredictable.~~the product in Japan. The Company ~~has considered the disruptions caused by~~ ~~COVID-19,~~ ~~including lower than forecasted sales, delays~~worked with COSMOTEC to ~~the speed of enrollment in the Company’s clinical trials that may, if successful, support commercial~~advance its application for approval ~~and new revenues in additional markets, and macroeconomic factors, that may impact its estimates. The Company has assessed the potential impact of~~ ~~COVID-19~~ on certain accounting matters including, but not limited to, the allowance for doubtful accounts, inventory reserves and return reserves, as of September 30, 2020 and through the date of this report. During the three months ended September 30, 2020, ~~COVID-19~~ had minor effects on the Company’s operations and financial position and cash flows. With respect to future operating results, it is not possible at this time to predict, with any degree of precision, the effects of ~~COVID-19.~~ Consequently, actual results for accounting estimates and assumptions, particularly those relating to the recoverability of certain intangible assets and estimates of expected credit losses on accounts receivable could differ from these estimates.

~~Redomiciliation~~

~~On June 29, 2020, the Company, a newly formed Delaware corporation, acquired all~~ of the ~~issued share capital of AVITA Medical , a then public company incorporated under the laws of the Commonwealth of Australia and former parent company of the AVITA Group. The acquisition was completed~~RECELL System in Japan pursuant to ~~a scheme of arrangement under Australian law,~~Japan’s Pharmaceuticals and Medical Devices Act (“PMDA”). In February 2022, COSMOTEC’s application for regulatory approval was approved by the ~~Federal Court~~PMDA with labeling for burns only. In September 2022, COSMOTEC commercially launched RECELL in Japan following Japan’s Ministry of ~~Australia on June 22, 2020,~~Health, Labor, and ~~by shareholders~~Welfare approval of ~~AVITA Medical on June 15, 2020 (the “~~~~Redomiciliation~~~~”). Under the Redomiciliation, all of the issued and outstanding ordinary shares of AVITA Medical, including those ordinary shares held in the form of American Depositary Shares (“~~~~ADSs~~~~”), were exchanged for newly issued shares of common stock of the AVITA Therapeutics or CHESS Depositary Interests (“~~~~CDIs~~”). This exchange was conducted on the basis of one share of common stock of AVITA Therapeutics for every 100 ordinary shares of AVITA Medical, effecting an ‘implicit consolidation’ or ‘reverse split’. The holders of ordinary shares of AVITA Medical received one CDI for every 20 ordinary shares held in AVITA Medical, and the holders of AVITA Medical ~~ADSs~~ (each of which previously represented 20 ordinary shares in AVITA Medical) received one share of common stock in AVITA Therapeutics for every five ADSs held. The common stock of AVITA Therapeutics began trading on The NASDAQ Stock Exchange LLC (“~~NASDAQ~~~~”) upon market open on July 1, 2020 under the same ticker code, “RCEL” as AVITA Medical’s ADSs were traded under prior to the Redomiciliation.~~

As part of the exchange of shares under the Redomiciliation, a reverse split was also simultaneously implemented such that the number of shares of common stock on issue in AVITA Therapeutics (as set out in the condensed consolidated financial statements) is less than the number of ordinary shares in AVITA Medical that was previously set out in the consolidated financial statements of AVITA Medical.

The Redomiciliation resulted in the domicile of the AVITA Group moving from Australia to the United States of America, with AVITA Therapeutics becoming the ultimate parent company of the AVITA Group. In addition, the existing listing of AVITA Medical ordinary shares on the Australian Securities Exchange (“~~ASX~~”) (as its primary listing) and AVITA Medical ADSs on NASDAQ (as its secondary listing) was inverted and replaced with a new listing of AVITA Therapeutics common stock on NASDAQ (as its primary listing) under the existing ticker symbol, “RCEL” and AVITA Therapeutics CDIs on the ASX (as its secondary listing) under the existing ticker symbol, AVH. Five CDIs traded on ASX are equivalent to one share of common stock traded on NASDAQ.reimbursement pricing.

~~As a result of the Redomiciliation, the reporting currency of the AVITA Group has changed from the Australian dollar to the U.S. dollar. In accordance with SEC regulation,~~ ~~S-X~~ ~~Rule 320 (e), the impact of the change in the reporting currency was included in a component of other comprehensive income (loss).~~

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited ~~condensed consolidated financial statements~~Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited ~~consolidated financial statements~~Consolidated Financial Statements and notes thereto included in the Company’s ~~annual report~~Annual Report on Form 10-K for the ~~fiscal year ended June 30, 2020~~year-ended December 31, 2022 filed with the SEC on ~~August 27, 2020~~February 23, 2023 and the Australian Securities Exchange ("ASX") on February 24, 2023 (the “Annual ~~Report~~”Report").

There have been no changes to the Company’s significant accounting policies as described in the ~~annual report~~Annual Report on Form 10-K that have had a material impact on the Company’s ~~condensed consolidated financial statements.~~Consolidated Financial Statements. See the summary of the Company’s significant accounting policies set forth in the notes to its ~~consolidated financial statements~~Consolidated Financial Statements included in the Annual Report.

Principles of Consolidation

The accompanying ~~condensed consolidated financial statements~~Consolidated Financial Statements include the accounts of the Company and its ~~wholly-owned~~wholly owned subsidiaries. ~~As a result of the Redomiciliation, the parent company of the AVITA Group changed from AVITA Medical to AVITA Therapeutics.~~ All intercompany transactions and balances have been eliminated upon consolidation.

Reclassification of prior year presentation

Certain prior year amounts within Other current liabilities have been reclassified to Current non-qualified deferred compensation liability, in the Consolidated Balance Sheets for consistency with current period presentation. These reclassifications had no effect on ~~consolidation.~~the reported results of operations or financial position.

Recent Accounting Pronouncements
No new accounting standards were adopted during the three-months and six-months ended June 30, 2023. The Company considers the applicability and impact of recent Accounting Standard Updates ("ASUs") issued by the Financial Accounting Standards Board ("FASB"). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company's Consolidated Financial Statements.

Use of Estimates

The preparation of the accompanying ~~condensed consolidated financial statements~~Consolidated Financial Statements in conformity with ~~U.S.~~ GAAP requires management to make estimates and assumptions that affect the reported amounts ~~including~~(including doubtful accounts, carrying value of long-lived ~~asset,~~assets, the useful lives of long-lived assets, ~~inventory,~~ accounting for marketable securities, income taxes, stock-based compensation, and ~~share-based compensation~~the stand-alone selling price for the Biomedical Advanced Research and Development Authority ("BARDA") contract) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.

Foreign Currency Translation and Foreign Currency Transactions

The financial position and results of operations of the Company’s operating non-U.S. subsidiaries are generally determined using the respective local currency as the functional currency of that subsidiary. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each period end. Income statement accounts are translated at the average rate of exchange prevailing during the period. Adjustments arising from the use of differing exchange rates from period to period are included in ~~accumulated other~~Other comprehensive gain (loss) in ~~shareholders’ equity.~~Stockholders’ Equity. Gains and losses resulting from foreign currency transactions ~~which are not material,~~ are included in ~~general~~General and administrative expenses in the ~~condensed consolidated statements~~Consolidated Statement of ~~operations.~~Operations. Amounts for the three-months ended June 30, 2023 were insignificant, and for the three-months ended June 30, 2022, the Company had a gain of $69,000. Gains and losses resulting from foreign currency transactions were a gain of $11,000 and gain of $47,000 for the six-months ended June 30, 2023 and 2022, respectively.

The Company’s non-operating subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period and nonmonetary assets and liabilities at historical rates. Gains and losses resulting from these remeasurements, and foreign currency transactions are included in General and administrative expenses in the Consolidated Statement of Operations. During the three-months ended June 30, 2023 and 2022, the Company recorded a loss of $6,000 and a gain of $7,000, respectively. During the six-months ended June 30, 2023 and 2022, the Company recorded a loss of $15,000 and a loss of $8,000, respectively

Comprehensive Loss

The components of comprehensive loss consist of net loss, foreign currency translation adjustments from the Company's subsidiaries not using the U.S. dollar as their functional currency and unrealized gains and losses in investments available-for-sale. The Company did not have reclassifications from other comprehensive loss to net loss during the three-months and six-months ended June 30, 2023 and 2022.

Revenue Recognition

The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services.

To determine revenue recognition for arrangements that are within the scope of Accounting Standard Codification (“ASC”) Topic 606, Revenue Recognition, the Company performs the following five steps:

Identify the contract with a customer

Identify the performance obligations

Determine the transaction price

Allocate the transaction price to the performance obligations

Recognize revenue when/as performance obligation(s) are satisfied

In order for an arrangement to be considered a contract, it must be probable that the Company will collect the consideration to which it is entitled for goods or services to be transferred. Once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised with each contract, determines whether those are performance obligations and the

related transaction price. The Company then recognizes the sale of goods based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

The Company’s revenue consists primarily of the sale of the RECELL System to hospitals, treatment centers, COSMOTEC and to BARDA (collectively, “customers”), predominately in the United States. The Company evaluated the BARDA contract and concluded that a portion of the arrangement, such as the procurement of the RECELL system and the emergency preparedness, represents a transaction with a customer and as such are in the scope of ASC 606. Amounts received from BARDA for the research and development of the Company’s product are classified as BARDA income in the Consolidated Statements of Operations and are accounted for under IAS 20 by analogy. For further details refer to BARDA Income and Receivables below.

Revenues for commercial customers (hospitals, treatment centers and COSMOTEC) are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such, revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. ~~Effective July 1, 2018, the Company adopted ASC 606,~~ ~~Revenue from Contracts with Customers~~, using the modified retrospective method applicable to all contracts that were not completed at the date of initial application. This update outlined a comprehensive new revenue recognition model designed to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard also required additional qualitative disclosures. Refer to Note 12 – Revenues for further information.

For the Company’s contracts that have an original duration of one year or less, the Company ~~used~~elected the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract ~~fulfilment~~fulfillment costs such as commissions and shipping and handling expenses as incurred.

For revenues related to the BARDA contract within the scope of ASC 606, the Company identified two performance obligations: (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services. Under this contract the Company promises to procure the product through a vendor management inventory arrangement and to stand ready to provide emergency deployment services related to the product. Emergency preparedness services include procuring necessary storage containers, housing, and maintaining the containers (and product), and providing shipping and handling services in the event of an emergency situation. This stand ready obligation is a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, over time as services are consumed.

The total transaction price for the portion of the BARDA contract that is within the scope of ASC 606 was determined to be $9.2 million. The transaction price was allocated on a stand-alone selling price basis as follows: $7.6 million to the procurement of the RECELL product, which is classified as Revenues when recognized in the Consolidated Statements of Operations and $1.6 million to the emergency deployment services which is classified as Revenues when recognized in the Consolidated Statements of Operations. The $1.6 million for emergency deployment includes variable consideration which is deemed immaterial to the contract as a whole. The Company estimated the stand-alone selling price of the procurement of the RECELL product based on historical pricing of the Company’s product at the initial execution of the contract. The Company estimated the stand-alone selling price of the emergency deployment services performed based on the Company’s projected cost of providing the services plus an applicable profit margin as denoted in the contract.

The Company’s performance obligations are either satisfied at a point in time or over time as services are provided. The product procurement performance obligation is satisfied at a point in time, upon transfer of control of the product. As such, the related revenue for these performance obligations is recognized at a point in time as Revenue within the Company’s Consolidated Statement of Operations. In addition to guidance under ASC 606, the Company recognizes revenue from the sales of RECELL product to BARDA for placement into vaccine stockpiles in accordance with SEC Interpretation, Commission Guidance regarding Accounting for Sale of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile (SNS). Under this guidance, revenue is recognized when product is placed in the BARDA vendor-managed inventory ("VMI") as control of the product has been transferred to the customer at the time of delivery to the VMI. RECELL units that have been delivered to BARDA have a product replacement obligation at no cost to BARDA due to the product’s limited shelf-life. The estimated cost of the expired inventory over the term of the contract is recognized on a per unit basis at the time of delivery. The liability is released upon replacement of the product along with a corresponding reduction to inventory. The emergency preparedness services performance obligation is satisfied over time. Revenue for the emergency deployment will be recognized on a straight-line basis during the term of the contract as services are consumed over time. Services recognized are included in Revenues within the Consolidated Statements of Operations. Contract costs to fulfill the performance obligations are incremental and expected to be recovered are capitalized and amortized on a straight-line basis over the term of the contract. Contract costs are included in Prepaids and other current assets in the Consolidated Balance Sheets. For further details refer to Note 5.

~~Concentrations~~Contract Liabilities

The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically 30-90 days, and do not include a financing component. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. For further details refer to Note 5.

Cost of Sales

Cost of sales related to products includes costs to manufacture or purchase, package, and ship the Company’s products. Costs also include relevant production overhead and depreciation and amortization. These costs are recognized when control of the product is transferred to the customer and revenue is recognized.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash held at deposit institutions and cash equivalents. Cash equivalents consist of short-term highly liquid investments with original maturities of three months or less from the date of purchase and consist primarily of money market funds. The Company holds cash at deposit institutions in the amount of $5.8 million and $4.1 million, of which $697,000 and $737,000 is denominated in foreign currencies in foreign institutions as of June 30, 2023 and December 31, 2022, respectively. As of June 30, 2023 and December 31, 2022, the Company held cash equivalents in the amount of $31.7 million and $14.1 million, respectively.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, BARDA receivables and other receivables. As of ~~September 30, 2020, and~~ June 30, ~~2020,~~2023 and December 31, 2022, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured ~~limits. Management believes that the Company is not exposed to significant credit risk due~~limits and subject to the ~~financial strength~~risk of ~~the depository institutions in which its cash is held.~~bank failure.

As of ~~September 30, 2020 and~~ June 30, ~~2020,~~ 2023 no single commercial customer accounted for more than 10% of net accounts receivable. As of December 31, 2022, one commercial customer accounted for more than 10% of total net accounts receivable. For the three-months and six-months ended June 30, 2023 and 2022, no single customer accounted for more than ~~10%~~10% of ~~net accounts receivable. For~~revenues. BARDA revenue for emergency deployment accounted for less than 1% of total revenues for the three-months and six-months ended June 30, 2023 and 2022. BARDA receivables for emergency preparedness services accounted for 4% and 2% of total BARDA receivables as of June 30, 2023 and December 31, 2022, respectively. See table below for breakdown of BARDA receivables (in thousands).


	As of
	June 30, 2023		December 31, 2022
BARDA procurement and emergency preparedness services	$	16	$	16
BARDA expense reimbursements		426		882
Total	$	442	$	898

Marketable Securities

We classify all highly liquid investments with original maturities of three months ~~ended September 30, 2020, no single customer accounted for~~or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date, and as long-term when the investments have remaining contractual maturities of more than ~~10%~~one year from the balance sheet date. Classification is determined at the time of ~~total revenues. For~~purchase and re-evaluated each balance sheet date. Short-term marketable securities represent investment of cash available for current operations.

All marketable securities, which consist of corporate debt securities, asset backed securities, U.S government agency obligations, U.S treasury and commercial paper are denominated in U.S. dollars, have been classified as “available-for-sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in Other comprehensive income (loss) and reported as a separate component of Stockholders' Equity until realized. Realized gains and losses on marketable securities are included in Other income in the ~~three~~accompanying Consolidated Statements of Operations. The cost of any marketable securities sold is based on the specific identification method. The amortized cost of marketable securities is adjusted for

amortization of premiums and accretion of discounts to maturity. Interest on marketable securities is included in Other income in the accompanying Consolidated Statements of Operations. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the maximum final maturity from the date of purchase is thirty-seven months ~~ended September 30, 2019, one customer accounted~~.

If necessary, the Company will recognize an allowance for ~~13%~~credit losses on available-for-sale debt securities on an individual basis and will no longer consider other-than-temporary impairment or immediately reduce the cost basis of ~~total revenues.~~the investment, provided that it is more likely than not that the security will be held to recovery or maturity. Further, the Company will recognize any improvements in estimated credit losses on available-for-sale debt securities immediately in earnings and reduce the existing allowance for credit losses. The Company will disaggregate its available-for-sale debt securities into the following categories: commercial paper, corporate debt, government and agency securities, asset backed securities and money market funds. The Company’s corporate bonds are comprised of predominantly high-grade corporate bonds while its government and agency securities are U.S. treasury bonds, and U.S. agency bonds. The Company has analyzed both corporate bonds and government and agency securities and identified that both types of securities have similar risk characteristics in that they are traded infrequently and have contractual interest rates and maturity dates.

To evaluate for impairment, management reviews credit rating changes, securities trends, interest rate movements and unrealized loss at the security level of the Company’s available-for-sale debt securities. If any of these give rise to a potential credit concern, the Company performs a discounted cash flow analysis to determine the credit portion of the impairment. The discounted cash flow analysis will be performed either internally or through the assistance of a qualified third party. Once the credit component of the impairment is determined, the Company will record the impaired amount as an allowance to the available-for-sale debt securities balance and as a charge to Other income in the accompanying Consolidated Statements of Operations, not to exceed the amount of the unrealized loss. The Company assesses expected credit losses at the end of each reporting period and adjusts the allowance through Other income.

BARDA Income and Receivables

The ~~AVITA Group~~Company was awarded ~~a Biomedical Advance Research and Development Authority (“~~the BARDA~~”) contract~~ grant in September 2015. Under this ~~arrangement~~grant, BARDA ~~supports~~supported the Company’s research and development for the Company’s product, including the ~~ongoing~~ U.S. clinical regulatory program targeted towards FDA PMA, ~~our~~ compassionate use ~~program,~~programs, clinical and health economics research, and U.S. pediatric burn programs. Currently, the BARDA contract is supporting the Company's clinical trial in soft-tissue reconstruction, which led to the full-thickness skin defect indication.

Consideration received under the BARDA ~~arrangement~~grant is earned and recognized under a cost-plus-fixed-fee arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs and a fixed-fee earned. Billings under the contracts are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, general and administrative expenses and a fixed fee.

The Company has concluded that grants under the BARDA ~~relationship is~~grant are not within the scope of ASC 606, as ~~it does~~they do not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605,Not-for-Profit-Entities-Revenue Recognition also does not apply, as the Company is a business entity, and the ~~payments~~grants are with governmental agencies or units. With respect to the BARDA ~~arrangement,~~grant, we considered the guidance in IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy. BARDA income and related receivables are recognized when there is reasonable assurance that the ~~amount~~grant will be received, and all attaching conditions have been complied with. When the ~~payment~~grant relates to an expense item, the ~~amount~~grant received is recognized as income over the period when the expense was incurred.

Leases

~~3. Accounting Standards Update~~

~~Recently Adopted Accounting Pronouncements~~

~~In August 2018, the FASB issued ASU~~ ~~No. 2018-15,~~~~Intangibles-Goodwill and~~ ~~Other-Internal-Use~~ ~~Software~~ ~~(Subtopic~~ ~~350-40):~~ ~~Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which provides new guidance on the accounting for implementation,~~ ~~set-up,~~ ~~and other upfront costs incurred in a hosted cloud computing arrangement. Under the new guidance, entities will apply the same criteria for capitalizing implementation costs as they would for an~~ ~~internal-use~~ software license arrangement. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This ASU can be adopted prospectively to eligible costs incurred on or after the date of adoption or retrospectively. Effective July 1, 2020, the Company adopted this standard using the prospective transition method. The adoption of this update did not have a material impact on the Company’s condensed consolidated financial statements.

~~Recent Accounting Pronouncements Not Yet Adopted~~

~~In December 2019, the FASB issued ASU~~ ~~2019-12,~~ ~~Simplifying the Accounting for Income Taxes~~~~, or ASU~~ ~~2019-12,~~ ~~which includes amendments to simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC 740,~~ ~~Income Taxes~~, or ASC 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. The new guidance is effective for the Company for annual periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption of the amendments is permitted. The Company ~~is currently evaluating the potential impact that the adoption of ASU~~ ~~2019-12~~ ~~will have on its condensed consolidated financial statements.~~

~~4. Leases~~

~~On July 1, 2019, the Company adopted Accounting Standards Codification No. 842,~~ ~~Leases~~~~, (“ASC 842”), which requires lessees to recognize~~has operating leases onfor corporate office space, manufacturing and a warehouse facility. The Company’s operating leases have remaining lease terms of one year to three years, some of which include options to renew the ~~balance sheet as a~~ ~~right-of-use~~ ~~asset (“ROU”) and lease liability.~~

lease. At contract inception, the Company determines whether the contract is a lease or contains a lease. A contract contains a lease if the Company is both able to identify an asset and can conclude it has the right to control the identified asset for a period of time. Leases with an initial term of twelve months or less are not recorded on the ~~condensed consolidated balance sheet.~~Consolidated Balance Sheets.

The Company has operating leases for corporate office space, manufacturing and warehouse facility. The Company has finance leases for equipment and furniture. The Company’s leases have remaining lease terms of less than one year to five years, some of which include options to renew the lease. Approximately $7,000 and $11,000 in finance leases was included in Other current liabilities as of September 30, 2020 and June 30, 2020, respectively.

Right-of-use (“ROU”) assets represent the Company’s right to control an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an ~~implicit~~explicit rate, the Company used its incremental borrowing rate (“IBR”) based on the information available at the commencement date in determining the discount rate used to present value lease payments. ~~The Company used the IBR on July 1, 2019 for its operating leases that commenced on or prior to that date.~~ In determining the IBR, the Company considered its credit rating and current market interest rates. The IBR used approximates the interest that the Company would be

required to pay for a collateralized loan over a similar term. Additionally, the Company used the portfolio approach when applying the discount rate selected based on the dollar amount and term of the obligation. Certain leases for equipment and furniture contain bargain purchase options and are classified as finance leases. The Company’s leases typically do not include any residual value guarantees or asset retirement obligations.

The Company’s lease terms are only for periods in which it has enforceable rights. A lease is no longer enforceable when both the lessee and the lessor each have the right to terminate the lease without permission from the other party with no more than an insignificant penalty. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. Lease expense is recognized on a straight-line basis over the lease term and is primarily included in General and administrative expenses in the accompanying Consolidated Statements of Operations.

The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all underlying asset classes. Some leases require variable payments for common area maintenance, property taxes, parking, insurance and other variable costs. The variable portion of lease payments is not included in operating lease ~~ROU~~ assets or ~~operating lease~~ liabilities. Variable lease costs are expensed when incurred.

Stock-Based Compensation

The Company records compensation expense for stock options and restricted stock units ("RSU") based on the fair market value of the awards on the date of grant. The fair value of stock-based compensation awards is amortized over the vesting period of the award. Compensation expense for performance-based awards is evaluated based on the number of shares ultimately expected to vest, evaluated each reporting period and based on management’s expectations regarding the relevant performance criteria. The Black-Scholes option pricing model and Monte Carlo Simulation are used to estimate the fair value of the time-based and performance-based options, respectively. Under ASU 2016-09, Compensation – Stock Compensation (“ASC 718”) Improvements to Employee Share-Based Payment Accounting, the Company elected to account for forfeitures as they occur.

The following assumptions were used in the valuation of stock options.

•

Expected volatility – determined using the average of the historical volatility using daily intervals over the expected term and the derived volatility using the longest term available of 12 months.

•

Expected dividends - based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future

•

Expected term – the expected term of the Company’s stock options for tenure only vesting has been determined utilizing the “simplified” method as described in the SEC’s Staff Accounting Bulletin No. 107 relating to share-based compensation. The simplified method was chosen because the Company has limited historical option exercise experience due to its short operating history of awards granted, with the first plan being established in 2016 which was primarily used for executive awards. Further, the Company does not have sufficient history of exercises in the U.S. market given the Company’s redomiciliation from Australia to the United States in 2020. The expected term of options with a performance condition or market condition was set to the contractual term of 10 years. The contractual term was used for options with a performance or market condition as these are primarily awarded to executives and the Company assumes that they will hold them longer than rank and file employees.

•

Risk-free interest rate – the risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for a period approximately equal to the expected term of the award.

Non-Qualified Deferred Compensation Plan Liability and Corporate-Owned Life Insurance Asset

The Company’s non-qualified deferred compensation plan (the "NQDC plan"), which became effective in October 2021, allows highly compensated key employees to elect to defer a portion of their salary, bonus and RSU awards to later years. Management determined that the cash deferrals under the NQDC plan shall be accounted for similarly to a defined benefit plan under ASC 715, Compensation – Retirement Benefits, and should follow accounting treatment that is similar to a cash balance plan. Management determined that the employee portion and employer portion of the deferred compensation should be recognized as a compensation expense with a corresponding credit to deferred compensation liability. The matching contribution will be accrued over the vesting period of two years with 25% vesting in the first year and 75% vesting in the second year. Employees aged 55 or older immediately vest in employer matching contributions. The change in the liability between each reporting period is accounted for as compensation expense with a corresponding adjustment to deferred compensation liability. Upon distribution, the Company will record the distribution as a decrease to deferred compensation liability with a corresponding credit to cash. The Company funds the NQDC plan through a Corporate-Owned Life Insurance (“COLI”). Per the ASC 325-30-25-1A, Investments – Other, COLI is

recorded as an asset on the Consolidated Balance Sheets as it does not meet the definition of a plan asset under ASC 715. The Company invests in COLI policies relating to its deferred compensation plan. Investments in COLI policies are recorded at their cash surrender values as of each balance sheet date. Changes in the cash surrender value during the period are recorded as a gain or loss in the Consolidated Statements of Operations in Other income.

Rabbi Trust

During April 2022, the Company established a rabbi trust for a select group of participants in which share awards granted under the 2020 Omnibus Incentive Plan (“2020 Plan”) and deferred under the NQDC plan may be deposited. In addition to the deferral of shares, the rabbi trust holds the assets in the COLI for the NQDC plan. The rabbi trust is an irrevocable trust, and no portion of the trust fund may be used for any purpose other than the delivery of those assets to the participants. The assets held in the rabbi trust are subject to the claims of our general creditors in the event of bankruptcy or insolvency. The value of the assets of the rabbi trust is consolidated into our financial statements.

The NQDC plan permits diversification of vested shares (common stock) into other equity securities subject to a six-month and one day holding period subsequent to vesting. Per ASC 710-10-25-15, accounting for deferred common stock will be under plan type C or D. Accounting will depend on whether or not the employee has diversified the common stock. Under Plan type C, diversification is permitted but the employee has not diversified. Under plan type D, diversification is permitted, and the employee has diversified.

For common stock that have not been diversified, the employer stock held in the rabbi trust is classified in a manner similar to treasury stock and presented separately on the Consolidated Balance Sheets as Company common stock held by the NQDC plan. The common stock will be recorded at the fair value of the stock at the time it vested, subsequent changes in the value of the common stock will not be recognized. The deferred compensation obligation is measured independently at fair value of the common stock with a corresponding charge or credit to compensation cost. The fair value is calculated as the product of the common stock and the closing price of the stock each reporting period.

Under plan type D, the accounting for the assets held by the rabbi trust is subject to the accounting pronouncements under applicable GAAP for each asset type. As diversified common stock will be invested in mutual funds, assets held by the rabbi trust will be subject to accounting under ASC 321 -Investments - Equity Securities. The deferred compensation obligation is measured independently at fair value of the underlying assets. As of June 30, 2023, none of the deferred common stock has been diversified.

Non-Qualified Deferred Compensation Stock Awards

In accordance with ASC 718, Compensation — Stock Compensation, the deferred RSU awards under the NQDC plan are classified as an equity instrument and changes in fair value of the amount owed to the participant are not recognized. As the plan permits diversification, presentation outside of permanent equity in accordance with ASR 268, Redeemable Preferred Stock is appropriate. The redemption amounts are based on the vested percentage and are recorded outside of equity as Non-qualified deferred compensation share awards on the Consolidated Balance Sheets. Deferred awards will be presented outside of permanent equity until the awards are vested. For further details refer to Note 17.

3. Marketable Securities

The following table summarizes the amortized cost and estimated fair values of debt securities available-for-sale:


	As of June 30, 2023
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Carrying Value
(in thousands)
Cash equivalents:
Money market funds	$	30,669	$	-	$	-		$	30,669
U.S. Treasury securities		999		1		-			1,000
Total cash equivalents	$	31,668	$	1	$	-		$	31,669
Current marketable securities:
U.S. Treasury securities	$	23,227	$	-	$	(69	)	$	23,158
Commercial paper		2,311		-		-			2,311
Corporate debt securities		1,422		-		(5	)		1,417
U.S. Government agency obligations		1,681		-		(5	)		1,676
Total current marketable securities	$	28,641	$	-	$	(79	)	$	28,562
Long-term marketable securities:
Asset backed securities	$	2,759	$	2	$	(7	)	$	2,754
Total long-term marketable securities	$	2,759	$	2	$	(7	)	$	2,754


	As of December 31, 2022
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Carrying Value
(in thousands)
Cash equivalents:
Money market funds	$	14,089	$	-	$	-		$	14,089
Current marketable securities:
U.S. Treasury securities	$	43,092	$	1	$	(393	)	$	42,700
Commercial paper		12,743		-		-			12,743
Corporate debt securities		3,865		-		(23	)		3,842
U.S. Government agency obligations		1,901		-		(8	)		1,893
Total current marketable securities	$	61,601	$	1	$	(424	)	$	61,178
Long-term marketable securities:
Asset backed securities	$	3,568	$	7	$	(3	)	$	3,572
U.S. Treasury securities		2,416		-		(6	)		2,410
U.S. Government agency obligations		949		-		(1	)		948
Total long-term marketable securities	$	6,933	$	7	$	(10	)	$	6,930

The maturities of debt securities available-for-sale are summarized in the following table using contractual maturities. Actual maturities may differ from contractual maturities due to obligations that are called or prepaid.


	As of June 30, 2023				As of December 31, 2022
(in thousands)	Amortized Cost		Carrying Value		Amortized Cost		Carrying Value
Due in one year or less	$	28,641	$	28,562	$	61,601	$	61,178
Due after one year through three years	$	2,759	$	2,754	$	6,933	$	6,930

Gross unrealized gains and losses on the Company’s marketable securities were an unrealized gain of $3,000 and an unrealized loss of $86,000 as of June 30, 2023, which resulted in a net unrealized loss of $83,000. Gross unrealized gains and losses on the Company’s marketable securities were an unrealized gain of $8,000 and an unrealized loss of $434,000 as of December 31, 2022, which resulted in a net unrealized loss of $426,000. As of June 30, 2023, and December 31, 2022, the Company did not recognize credit losses. The Company has accrued interest income of $168,000 as of June 30, 2023, and December 31, 2022, in Prepaids and other current assets.

4. Fair Value Measurements

The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:

Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2: Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Inputs are unobservable inputs for the asset or liability.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:


	As of June 30, 2023
(in thousands)	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	30,669	$	-	$	-	$	30,669
U.S. Treasury securities		-		1,000		-		1,000
Total Cash equivalents	$	30,669	$	1,000	$	-	$	31,669
Current marketable securities:
U.S. Treasury securities	$	-	$	23,158	$	-	$	23,158
Commercial paper		-		2,311		-		2,311
Corporate debt securities		-		1,417		-		1,417
U.S. Government agency obligations		-		1,676		-		1,676
Total current marketable securities	$	-	$	28,562	$	-	$	28,562
Long-term marketable securities:
Asset backed securities	$	-	$	2,754	$	-	$	2,754
Total long-term marketable securities	$	-	$	2,754	$	-	$	2,754
Total marketable securities and cash equivalents	$	30,669	$	32,316	$	-	$	62,985


	As of December 31, 2022
(in thousands)	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	14,089	$	-	$	-	$	14,089
Current marketable securities:
U.S. Treasury securities		-		42,700		-		42,700
Commercial paper		-		12,743		-		12,743
Corporate debt securities		-		3,842		-		3,842
U.S. Government agency obligations		-		1,893		-		1,893
Total current marketable securities	$	-	$	61,178	$	-	$	61,178
Long-term marketable securities:
Asset backed securities	$	-	$	3,572	$	-	$	3,572
U.S. Treasury securities		-		2,410		-		2,410
U.S. Government agency obligations		-		948		-		948
Total long-term marketable securities	$	-	$	6,930	$	-	$	6,930
Total marketable securities and cash equivalents	$	14,089	$	68,108	$	-	$	82,197

The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of commercial paper, U.S. Government agency obligations, corporate debt securities, asset backed securities and U.S Treasury securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of June 30, 2023 and December 31, 2022, the Company had no investments that were measured using unobservable (Level 3) inputs. There were no transfers between fair value measurement levels as of June 30, 2023 or December 31, 2022.

5. Revenues

Revenues

The Company’s revenue consists of sale of the RECELL System to hospitals, treatment centers and COSMOTEC (“commercial customers”) and to BARDA (collectively “customers”), predominately in the United States. In addition, the Company records service revenue for the emergency preparedness services provided to BARDA.

Performance Obligations

For commercial contracts, we identified the hospital, treatment center, or COSMOTEC as the customer in Step 1 of the 5-step model of ASC 606 and have determined a contract exists with those customers. As these contracts typically have a single performance obligation (i.e., product delivery), no allocation of the transaction price is required in Step 4 of the model. Control of the product is transferred to the customer at a point in time, at the point in time at which the goods are either shipped or delivered to the customers’ facilities, depending on the terms of the contract. The transaction price is stated within the contract and is therefore fixed consideration. The transaction price does not include the sales tax that is imposed by governmental authorities.

For the contract with BARDA, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services. The Company’s performance obligations are either satisfied at a point in time or over time as services are provided. The product procurement performance obligation is satisfied at a point in time, upon transfer of control of the product. RECELL units that have been delivered to BARDA have a product replacement obligation at no cost to BARDA due to the product’s limited shelf-life. The estimated cost of the expired inventory over the term of the contract is recognized on a per unit basis at the time of delivery. The liability is released upon replacement of the product along with a corresponding reduction to inventory. The Company has estimated deferred cost of approximately $130,000 and $194,000 as of June 30, 2023 and December 31, 2022, respectively, for the rotation cost of the product and are included Other current liabilities in the Consolidated Balance Sheets. The emergency preparedness services performance obligation is satisfied over time. Revenue for the emergency deployment will be recognized on a straight-line basis during the term of the contract as services are consumed over time. Services recognized for the three-months ended June 30, 2023 and 2022, were $67,000 and $93,000, respectively. Services recognized for the six-months ended June 30, 2023 and 2022, were $160,000 and $186,000, respectively. Services are included in Revenues within the Consolidated Statements of Operations. Contract costs to fulfill the performance obligation that are incremental and are expected to be recovered are capitalized and amortized on a straight-line basis over the term of the contract. As of June 30, 2023 and December 31, 2022, contract costs of $126,000 and $252,000 are included in Prepaids and other current assets in the Consolidated Balance Sheets.

Remaining Performance Obligations

Revenues from remaining performance obligations are calculated as the dollar value of the remaining performance obligations on executed contracts. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to the Company’s existing customer agreements is $557,000 and $698,000 as of June 30, 2023 and December 31, 2022, respectively. Approximately $149,000 as of June 30, 2023 and $274,000 as of December 31, 2022, of the total balance relates to our July 2020 contract with BARDA for the purchase, delivery and storage of RECELL Systems for emergency response preparedness for a period of three years. The Company expects to recognize these amounts as services are provided to BARDA. We are contracted to manage this inventory of product until the federal government requests shipment or at contract termination on December 31, 2023. The remaining balance of $408,000 and $424,000 as of June 30, 2023 and December 31, 2022, respectively, relate to our contract with COSMOTEC. The Company expects to recognize these amounts as revenue on a straight-line basis over the term of the contract with COSMOTEC.

Variable Consideration

The Company evaluates its contracts with customers for forms of variable consideration, which may require an adjustment to the transaction price based on their estimated impact. For commercial customers, revenue from the sale of goods is recognized net of volume discounts. The Company uses the expected value method when estimating variable consideration. Revenue is only recognized to the extent that it is probable that a significant reversal will not occur. Variable consideration under the BARDA contract is not material to the Consolidated Financial Statements.

Contract Assets and Contract Liabilities

Contract assets include amounts related to the Company’s contractual right to consideration for both completed and partially completed performance for which the Company does not have the right to payment. As of the period ended June 30, 2023 and December 31, 2022, the Company does not have any contract assets.

Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. The Company had $557,000 and $698,000 of contract liabilities as of June 30, 2023 and December 31, 2022, respectively. As of June 30, 2023 and December 31, 2022, a total of $183,000 and $0, respectively, was included in Other current liabilities and $374,000 and $698,000, respectively, in Contract liabilities in the Consolidated Balance Sheets. The balance relates to the unsatisfied performance obligation for emergency preparedness under the BARDA and amounts received from COSMOTEC. The Company recognized $67,000 and $93,000 of revenue from BARDA for amounts included in the beginning balance of contract liabilities for the three-months ended June 30, 2023 and 2022, respectively, and $160,000 and $186,000 for the six-months ended June 30, 2023 and 2022, respectively. The Company recognized $8,000 and $17,000 of revenue from COSMOTEC for amounts included in the beginning balance of contract liabilities for the three-months and six-months ended June 30, 2023. The Company did not recognize any the amounts of revenue included in the beginning balance of contract liabilities for the three-months and six-months ended June 30, 2022.

Cost to Obtain and Fulfill a Contract

Commercial contract fulfillment costs include commissions and shipping expenses. The Company has opted to immediately expense the incremental cost of obtaining a contract when the underlying related asset would have been amortized over one year or less. The Company generally does not incur costs to obtain new contracts.

BARDA Contract Costs

Cost to fulfill the BARDA emergency preparedness performance obligation, which primarily consist of billed costs to BARDA incurred in connection with the emergency deployment services, are incremental and expected to be recovered. Costs are capitalized and amortized on a straight-line basis over the term of the contract. As of June 30, 2023, and December 31, 2022, the Company had $126,000 and $252,000 of contracts costs included in Prepaids and other current assets in the Consolidated Balance Sheets. Amortization expense related to deferred contract costs was $85,000 and $84,000 for the three-months ended June 30, 2023 and 2022, respectively, and $170,000 and $169,000 for the six-months ended June 30, 2023 and 2022, respectively, and are classified as Cost of sales on the accompanying Consolidated Statements of Operations. There was no impairment loss in relation to deferred contract costs during the three-months and six-months ended June 30, 2023, and 2022.

Disaggregated Revenue

The Company disaggregates revenue from contracts with customers into geographical regions and by customer type. As noted in the segment footnote, the Company’s business consists of one reporting segment. A reconciliation of disaggregated revenue by geographical region and customer type is provided in Segment Note 11.

6. Leases

During February 2023, the Company remeasured the lease liability for an office lease due to a change in the lease term. As a result of the remeasurement of the lease liability, there was an increase of approximately $1.1 million to the operating lease ROU assets and operating lease liabilities. There was no impact on earnings as a result of the lease modification.

The following table sets forth the Company’s operating lease ~~expense~~expenses which are included in ~~general~~General and administrative expenses in the ~~consolidated statements~~Consolidated Statements of ~~operations~~Operations (in thousands):


					Three-Months Ended				Six-Months Ended
	Three Months ended September 30, 2020		Three Months ended September 30, 2019		June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Operating lease cost	$	175	$	175	$	197	$	194	$	395	$	388
Variable lease cost		12		12		13		13		26		25

Total lease cost	$	187	$	187	$	210	$	207	$	421	$	413

Supplemental cash flow information related to ~~operating~~Operating leases for the ~~three months~~three-months and six-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019~~2022 was as follows (in thousands):


					Three-Months Ended				Six-Months Ended
	Three Months ended September 30, 2020		Three Months ended September 30, 2019		June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflows from operating leases	$	171	$	166	$	205	$	199	$	410	$	397

Supplemental balance sheet information, as of ~~September 30, 2020 and~~ June 30, ~~2020~~2023 and December 31, 2022, related to operating leases was as follows (in ~~thousands)~~thousands, except for Operating lease weighted average remaining lease term and operating lease weighted average discount rate):


							As of
	As of September 30, 2020			As of June 30, 2020			June 30, 2023			December 31, 2022
Reported as:
Operating lease right-of-use assets	$	2,216		$	2,347		$	1,651		$	851

Total right-of-use assets	$	2,216		$	2,347		$	1,651		$	851

Other current liabilities:
Other current liabilities:
Operating lease liabilities, short-term	$	548		$	533		$	656		$	612
Operating lease liabiltiies, long term		1,776			1,917

Operating lease liabilities, long term								1,047			306
Total operating lease liabilities	$	2,324		$	2,450		$	1,703		$	918

Operating lease weighted average remaining lease term (years)		3.66			3.91			2.73			1.44
Operating lease weighted average discount rate		7.50	%		7.50	%		7.93	%		6.71	%

As of ~~September~~June 30, ~~2020,~~2023, maturities of the Company’s operating lease liabilities are as follows (in thousands):


	Operating Leases			Operating Leases
Remaining 2021	$	524
2022		717
2023		740
Remainder of 2023				$	345
2024		588			741
2025 and thereafter		87

2025					441
2026					377
Total lease payments	$	2,656			1,904
Less imputed interest		(332	)		(201	)

Total operating lease liabilities	$	2,324		$	1,703

As of ~~September~~June 30, ~~2020, there were no leases entered into~~2023, the Company had an office space lease that ~~had not yet commenced.~~subsequently commenced July 2023 for a term of 5-years with an average monthly rent of approximately $25,000.

5.7. Inventory

The composition of ~~inventories~~inventory is as follows (in thousands):


					As of
	September 30, 2020		June 30, 2020		June 30, 2023		December 31, 2022
Raw materials	$	1,035	$	947	$	1,882	$	1,131
Work in process inventory		271		—
Work in process						491		384
Finished goods		351	$	178		685		610

Total inventory	$	1,657	$	1,125	$	3,058	$	2,125

The Company has reduced the carrying value of its inventories to reflect the lower of cost or net realizable value. Charges for estimated excess and obsolescence are recorded in ~~cost~~Cost of sales in the ~~condensed consolidated statement~~Consolidated Statements of ~~operations. Inventory impairments recognized in cost of sales are a result of expired product~~Operations and were ~~$43,000~~$2,000 and ~~$53,000~~$61,000 for the ~~three months~~three-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019,~~2022, respectively, and $68,000 and $158,000 for the six-months ended June 30, 2023 and 2022, respectively.

6.8. Intangible Assets

The composition of intangible assets, net is as follows (in thousands):


			As of September 30, 2020							As of June 30, 2020									As of June 30, 2023							As of December 31, 2022
	Weighted Average Life		Gross Amount		Accumulated Amortization			Net Carry Amount		Gross Amount		Accumulated Amortization			Net Carry Amount		Weighted Average Life		Gross Amount		Accumulated Amortization			Net Carry Amount		Gross Amount		Accumulated Amortization			Net Carry Amount
Patent 1		3	$	237	$	(121	)	$	116	$	235	$	(101	)	$	134		3	$	17	$	(16	)	$	1	$	17	$	(16	)	$	1
Patent 2		14		105		(9	)		96		74		(9	)		65		13		138		(33	)		105		137		(28	)		109
Patent 3		15		127		(11	)		116		125		(9	)		116		14		195		(46	)		149		194		(39	)		155
Patent 5		20		46		(1	)		45		26		—			26		19		98		(9	)		89		89		(6	)		83
Patent 6																		20		44		(5	)		39		43		(4	)		39
Patent 7																		13		2		-			2		2		-			2
Patent 8																		19		10		(1	)		9		13		-			13
Patent 10																		19		3		-			3		3		-			3
Patent 11																		19		6		(1	)		5		6		-			6
Trademarks		Indefinite		30		—			30		23		—			23	Indefinite			54		-			54		54		-			54

Total intangible assets			$	545	$	(142	)	$	403	$	483	$	(119	)	$	364			$	567	$	(111	)	$	456	$	558	$	(93	)	$	465

For the three-months and six-months ended June 30, 2023 the Company recorded an impairment charge of approximately $4,000 in General and administrative expenses in the Consolidated Statement of Operations. During the ~~three months~~three-months and six-months ended ~~September~~June 30, ~~2020 and 2019,~~2022, the Company did not identify any events or changes in circumstances that indicated that the carrying value of its intangibles may not be recoverable. As such, there was no impairment of intangibles assets recognized for the ~~three months~~three-months and six-months ended ~~September~~June 30, ~~2020 and 2019.~~2022. Amortization expense of intangibles included in the ~~condensed consolidated statements~~Consolidated Statements of ~~operations was $23,000 and $0~~Operations were $8,000 for the ~~three months~~three-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019,~~2022, respectively, and $17,000 and $42,000 for the six-months ended June 30, 2023 and 2022, respectively.

The Company expects the future amortization of amortizable intangible assets held at ~~September~~June 30, ~~2020~~2023 to be as follows (in thousands):

Estimated Amortization
Expense

Remainder of 2021
   $ 70
2022
   67
2023
   21
2024
   21
2025
   21
2026 and thereafter
   173


Total
   $ 373


	Estimated Amortization Expense
Remainder of 2023	$	17
2024		34
2025		34
2026		34
2027		33
2028		33
Thereafter		217
Total	$	402

~~7. Property,~~9. Plant and Equipment

The composition of property, plant and equipment, net is as follows (in thousands):


									As of
	Useful Lives	As of September 30, 2020			As of June 30, 2020			Useful Lives	June 30, 2023			December 31, 2022
Computer equipment	3 years	$	825		$	802		3 years	$	889		$	755
Computer software	3 years		496			369		3 years		980			871
Construction in progress			91			138				423			258
Furniture and fixtures	7 years		427			425		7 years		616			439
Laboratory equipment	5 years		233			194		5 years		696			643
Leasehold improvements	Lesser of life or lease term		216			216		Lesser of life or lease term		257			257
RECELL Moulds	5 years		130			100
RECELL moulds								5 years		128			129
Less: accumulated amortization and depreciation			(1,069	)		(881	)			(2,391	)		(2,152	)

Total property, plant and equipment, net		$	1,349		$	1,363

Total plant and equipment, net									$	1,598		$	1,200

Depreciation expense related to plant and equipment was ~~$188,000~~$137,000 and ~~$66,000~~$129,000 for the ~~three months~~three-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019,~~2022 respectively, and $264,000 and $258,000 for the six-months ended June 30, 2023 and 2022, respectively. For the three-months and six-months ended June 30, 2023, the Company recorded an impairment charge of approximately $3,000 in General and administrative expenses in the Consolidated Statement of Operations. During the three-months and six-months ended June 30, 2022, the Company did not identify any events or changes in circumstances that indicated that the carrying value of its plant and equipment may not be recoverable. As such, there was no impairment of plant and equipment recognized for the three-months and six-months ended June 30, 2022.

~~8. Prepaids and~~10. Other Current and Long-Term Assets and Liabilities

Prepaids and other current assets consisted of the following (in thousands):


					As of
	As of September 30, 2020		As of June 30, 2020		June 30, 2023		December 31, 2022
Prepaid expenses	$	850	$	792	$	1,375	$	921
Lease deposits		98		123		-		110
Accrued investment income						168		168
BARDA contract costs						126		252
Other receivables		106		75		525		127

Total prepaids and other current assets	$	1,054	$	990	$	2,194	$	1,578

Prepaid expenses primarily consist of prepaid benefits and insurance.

Other long-term assets consisted of the following (in thousands):


	As of
	June 30, 2023		December 31, 2022
Long-term lease deposits	$	189	$	25
Long-term prepaids		96		97
Total other long-term assets	$	285	$	122

Other current liabilities consisted of the following (in thousands):


	As of
	June 30, 2023		December 31, 2022
Operating lease liability	$	656	$	612
BARDA deferred costs		130		194
BARDA deferred revenue		183		-
Other current liabilities		232		184
Total other current liabilities	$	1,201	$	990

11. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. Long-lived assets ~~were~~are primarily located in the United States as of ~~September 30, 2020 and~~ June 30, ~~2020~~2023, and December 31, 2022, with an insignificant amount located in Australia and the United Kingdom.

Revenue by region for the ~~three months~~three-months and six-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019~~2022 were as follows (in thousands):


					Three-Months Ended				Six-Months Ended
	Three Months ended September 30, 2020		Three Months ended September 30, 2019		June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Revenue:
United States	$	4,970	$	3,130	$	10,992	$	8,278	$	20,417	$	15,676
Foreign:
Japan						708		-		1,729		-
Australia		80		46		33		29		95		116
United Kingdom		10		74		20		28		62		82

Total	$	5,060	$	3,250	$	11,753	$	8,335	$	22,303	$	15,874

~~10. Contingencies~~

Revenue and cost of sales by customer type for the three-months and six-months ended June 30, 2023 and 2022 were as follows (in thousands):


	Three-Months Ended				Six-Months Ended
	June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Revenue:
Commercial sales	$	11,686	$	8,242	$	22,143	$	15,688
BARDA:
Services for emergency preparedness		67		93		160		186
Total	$	11,753	$	8,335	$	22,303	$	15,874


	Three-Months Ended				Six-Months Ended
	June 30, 2023		June 30, 2022		June 30, 2023			June 30, 2022
Cost of sales:
Commercial cost	$	2,108	$	1,302	$	3,724		$	3,007
BARDA:
Product cost		11		-		(23	)		(12	)
Emergency preparedness service cost		85		84		170			169
Total	$	2,204	$	1,386	$	3,871		$	3,164

12. Contingencies

The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. As of ~~September 30, 2020 and~~ June 30, ~~2020,~~2023 and December 31, 2022, the Company did ~~not~~not have any outstanding or threatened litigation that would have a material impact toon the financial statements.

~~11.~~13. Common and Preferred Stock

~~On June 29, 2020, a statutory scheme of arrangement under Australian law to effect a redomiciliation of the AVITA Group from Australia to the United States of America was implemented (the “~~~~Scheme~~~~”). The Scheme was approved by shareholders on June 15, 2020 and approved by the Federal Court of Australia on June 22, 2020.~~

Pursuant to the Scheme, all ordinary shares in AVITA Medical, the former parent company of the AVITA Group, were exchanged for shares of common stock in AVITA Therapeutics. As a result, AVITA Therapeutics became the sole shareholder of AVITA Medical and the new parent company of the AVITA Group. In conjunction with the Scheme, an implicit reverse split on a 1 for 100 basis was implemented whereby shareholders of AVITA Medical received one share of common stock in AVITA Therapeutics for every 100 ordinary shares held in AVITA Medical.

~~Under the Scheme, eligible shareholders in AVITA Medical received consideration in the form of:~~

~~five CDIs in AVITA Therapeutics for every 100 ordinary shares in AVITA Medical that were held by them; or~~

~~one share of common stock in AVITA Therapeutics for every 5 ADS~~s ~~in AVITA Medical that were held by them.~~

The Company’s CHESS Depositary Interests (“CDIs”) are quoted on the ASX under ~~AVITA Medical’s existing ASX~~the ticker code, “AVH”. The Company’s shares of common stock are quoted on ~~NASDAQ~~the Nasdaq Capital Market (“Nasdaq”) under ~~AVITA Medical’s existing NASDAQ~~the ticker code, “RCEL”. One share of common stock on ~~NASDAQ~~Nasdaq is equivalent to five CDIs on the ASX.

As a result of the ‘implicit consolidation’ that occurred under the Scheme, the number of shares of common stock on issue in the Company (as set out in the condensed consolidated financial statements) is less than the number of ordinary shares in AVITA Medical that was previously set out in the consolidated financial statements of AVITA Medical. All common share amounts included in the condensed consolidated financial statements have been retroactively reduced by a factor of one hundred and all per share amounts have been increased by a factor or one hundred, with the exception of the Company’s common stock par value.

The Company is authorized to issue 200,000,000 shares of common stock, par value ~~$0.0001~~$0.0001 per share, and 10,000,000 shares of preferred stock, par value ~~$0.0001~~$0.0001 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of ~~September 30, 2020, and~~ June 30, ~~2020, 21,623,287~~2023, and ~~21,467,912~~December 31, 2022, 25,447,615and 25,208,436 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were ~~outstanding.~~

~~12. Revenues~~

~~Revenues~~

~~The Company’s revenue consists of sale of the RECELL System to hospitals or other treatment centers (“customers”), predominately in the United States.~~

~~Contract Assets and Contract Liabilities~~

The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically ~~30-90~~ ~~days, and do not include a financing component.~~

Contract assets include amounts related to the Company’s contractual right to consideration for both completed and partially completed performance for which the Company does not have the right to payment. As of September 30, 2020, and June 30, 2020, the Company did not haveoutstanding during any ~~contract assets.~~

Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. The Company had $435,000 and $435,000 of contract liabilities as of September 30, 2020 and June 30, 2020, respectively. For the three months ended September 30, 2020 and 2019, revenue recognized from amounts included in the beginning balance of contract liabilities was not significant.period.

~~Remaining Performance Obligations~~

~~13. Share-Based~~14. Stock-Based Payment Plans

Overview of Employee ~~Share-Based~~Stock-Based Compensation Plans

~~In November 2014, our~~

Our former parent company, AVITA Medical Pty Limited, adopted the Employee Share Plan and the Incentive Option Plan (collectively, the ~~“2016 Plans”~~“2016 Plans”). ~~The 2016 Plans previously authorized~~Upon completion of the ~~issuance~~redomiciliation of ~~stock options or other share-based instruments representing up~~the Company from Australia to ~~7.5% of outstanding capital of AVITA Medical. Any increase~~the United States in ~~the maximum number of shares issuable under the 2016 Plans was subject to shareholder approval or to an increase in the total number of ordinary shares outstanding. Upon~~ June 2020 (“Redomiciliation”), the 2016 Plans were terminated with respect to future grants and accordingly, there are no more shares available to be issued under the 2016 Plans. In addition, upon completion of the Redomiciliation, the Company had an implicit ~~100-1~~consolidation or reverse stock split of 100:1 and all share information presented below in relation to the 2016 Plans has been presented on a reverse stock split basis. During November 2020, the Company filed a registration statement on Form S-8 to register a total of 1,750,000 shares of common stock ~~basis. At~~which may be issued pursuant to the terms of the 2020 Plan.During June 2023, the Company filed a registration statement on Form S-8 to register an additional 2,500,000 shares of common stock under the 2020 Plan. The increase in shares available for issuance was a result of the stockholders of AVITA Medical, Inc. approving an amendment to the 2020 Plan on June 6, 2023 at the Company’s 2023 Annual Meeting of Stockholders ~~that~~(the “2023 Annual Meeting”).

On December 22, 2021, the Company’s stockholders approved the issuance of options and RSUs to the Board of Directors in accordance with ASX rules. These awards are subject to the vesting and performance conditions as denoted in the individual agreements (collectively, the "2021 Annual Meeting Awards"). On December 12, 2022, the Company's stockholders approved the issuance of options and RSUs to the Board of Directors and the CEO in accordance with ASX rules. These awards are subject to vesting conditions as denoted in the individual agreements (collectively, the "2022 Annual Meeting Awards"). On June 6, 2023, the Company's stockholders approved the issuance of options and RSUs to the Board of Directors and the CEO in accordance with ASX rules. These awards are subject to vesting conditions as denoted in the individual agreements (collectively, the "2023 Annual Meeting Awards").

The 2020 Plan provides for the grant of the following Grants: (a) Incentive Stock Options, (b) Nonstatutory Stock Options, (c) Stock Appreciation Rights, (d) Restricted Stock Grants, (e) Restricted Stock Unit Grants, (f) Performance Grants, and (g) Other Grants. The 2020 Plan will be ~~held on November 9,~~administered by the Compensation Committee or by the Board acting as the Compensation Committee. Subject to the general purposes, terms and conditions of the 2020 Plan, applicable law and any charter adopted by the ~~Company intends~~Board governing the actions of the Compensation Committee, the Compensation Committee will have full power to ~~seek shareholder approval for a new employee~~implement and carry out the 2020 Plan. Without limitation, the Compensation Committee will have the authority to interpret the plan, approve persons to receive grants, determine the terms and number of shares of the grants, determine vesting and exercisability of grants, and make all other determinations necessary or advisable in connection with the administration of this Plan.

The contractual term of stock option ~~plan.~~awards granted under the 2020 Plan is ten years from the grant date. Unless otherwise specified, the vesting periods of options and RSUs granted under the 2020 Plan are: (i) vest over a three-year or four-year period in equal installments at the end of each year from the date of grant, and /or (ii) subject to other performance criteria and hurdles, as determined by the Compensation Committee.

~~Share-Based~~

Stock-Based Payment Expenses

~~Share-based~~

Stock-based payment transactions are recognized as compensation ~~cost~~expense based on the fair value of the instrument on the date of grant. The Company uses the ~~binomial option valuation model~~graded-vesting method to ~~estimate~~recognize compensation expense. Compensation cost is reduced for forfeitures as they occur in accordance with ASU 2016-09, Simplifying the ~~grant date fair value of employee stock options.~~

~~During the three months ended September 30, 2020 and 2019, the~~Accounting for Share-Based Payment. The Company recorded stock-based compensation expense of ~~$3.2~~$1.1 million and ~~$672,000,~~$1.4 million for the three-months ended June 30, 2023 and 2022, respectively, and $3.8 million and $4.3 million for the six-months ended June 30, 2023 and 2022, respectively. No income tax benefit was recognized in the ~~condensed consolidated statement~~Consolidated Statements of ~~comprehensive loss~~Operations for ~~share-based~~stock-based payment arrangements for the ~~three months~~three-months and six-months ended ~~September~~June 30, ~~2020~~2023, and ~~2019.~~2022.

The Company has included stock-based compensation expense as part of operating expenses in the accompanying Consolidated Statements of Operations as follows:


	Three-Months Ended				Six-Months Ended
(In thousands)	June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Sales and marketing expenses	$	76	$	285	$	401	$	614
General and administrative expenses		818		983		2,908		3,310
Research and development expenses		249		146		474		422
Total	$	1,143	$	1,414	$	3,783	$	4,346

A summary of ~~stock~~share option activity ~~under the employees share option planarrangement~~ as of ~~September~~June 30, ~~2020~~2023, and changes during the period ~~then~~ ended is presented below:


	Service Only Stock Options			Performance Based Stock Options			��	Total Stock Options			Service Only Share Options			Performance Based Share Options			Total Share Options
Outstanding at June 30, 2020		904,353			356,171				1,260,524
Outstanding shares at December 31, 2022												1,724,252			511,194			2,235,446
Granted												889,193			-			889,193
Exercised		(3,538	)		—				(3,538	)		(116,529	)		(30,000	)		(146,529	)
Expired		(1,636	)		(2	)			(1,638	)		(59,125	)		(178,156	)		(237,281	)
Forfeited		(21,778	)		—				(21,778	)		(58,413	)		(6,958	)		(65,371	)

Outstanding at September 30, 2020		877,401			356,169				1,233,570

Exercisable at September 30, 2020		296,803			298,897				595,700
Outstanding shares at June 30, 2023												2,379,378			296,080			2,675,458
Exercisable at June 30, 2023												720,303			235,896			956,199

Restricted Stock Units

Restricted stock units (“~~RSUs~~”) are granted to executives as part of their long-term incentive compensation. RSUs granted to directors as a result of stockholder approval 2021 Annual Meeting, 2022 Annual Meeting and 2023 Annual Meeting are issued pursuant to award agreements between the Company and the holders of such securities. These RSU awards ~~are~~were approved by the Compensation ~~Committee as determined necessary. The~~Committee. All RSU awards ~~have a contractual term of 10 years and~~ vest in accordance with the tenure or performance conditions as determined by the Compensation ~~Committee.~~Committee and set out in the contracts between the Company and the holders of such securities. The grant date fair value is determined based on the price of the Company stock ~~on the ASX~~price on the date of ~~grant. RSUs primarily consist of awards to the Chief Executive Officer and other executives.~~

grant (stock price determined on Nasdaq).

A summary of the status of the Company’s unvested ~~shares~~RSUs as of ~~September~~June 30, ~~2020,~~2023, and changes that occurred during the ~~three months ended September 30, 2020,~~period is presented below:


	Service Condition RSU		Performance Condition RSUs			Total RSU
Unvested RSUs outstanding at June 30, 2020		95,013		244,346			339,359
Unvested Shares									Tenure-Based RSUs			Performance Condition RSUs			Total RSUs
Unvested RSUs outstanding at December 31, 2022										394,872			65,646			460,518
Granted										57,798			-			57,798
Vested		—		(151,837	)		(151,837	)		(76,900	)		(15,750	)		(92,650	)
Forfeited		—		(2	)		(2	)		(39,250	)		(7,875	)		(47,125	)

Unvested RSUs outstanding at September 30, 2020		95,013		92,507			187,520

Unvested RSUs outstanding at June 30, 2023										336,520			42,021			378,541

~~14. Income Taxes~~2021 Annual Meeting Awards

At June 30, 2020, the Company and its subsidiaries had net operating loss carryforwards for U.S. federal, state, United Kingdom, and Australian income tax purposes of $88.5 million, $57.5 million, $29.8 million, and $34.1 million, respectively. The net operating loss carryforwards may be subject

Awards to ~~limitation regarding their utilization against taxable income in future periods due to “change of ownership” provisions~~non-executive members of the ~~Internal Revenue Code~~Board of Directors ("Director awards") under the 2021 Annual Meeting Awards

The Director awards that were granted in 2021 consist of an aggregate 68,600 options and ~~similar state~~RSUs as follows:

•

41,400 tenure-based options and ~~foreign provisions. Of these carryforwards, $21.7 million will expire, if not utilized, in various years through 2038. The remaining loss carryforwards have no expiration.~~

~~In assessing~~RSUs (15,300 options and 26,100 RSUs) vesting 12 months from the recoverability of its deferred tax assets, the Company considers whether it is more likely than not that its deferred assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. The Company considers all positivegrant date.

Includes 6,900 tenure-based options and ~~negative evidence when determining the amount~~RSUs (4,350 RSUs and 2,550 options) were granted to each of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Based upon the weight of available evidence including the uncertainty regarding the Company’s ability to utilize certain net operating losses and tax credits in the future, the Company has established a full valuation allowance against all its net deferred tax assets. The deferred tax assets are primarily net operating loss carryforwards for which management has determined it is more likely than not that the deferred tax assets will not be realized.

~~The Company recognizes the tax benefit from an uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities~~six non-executive board members based on the ~~technical merits~~vesting terms detailed above.

•

27,200 tenure-based options and RSUs (9,850 options and 17,350 RSUs) vesting on the first, second and third anniversary of the ~~position.~~ grant date in equal amounts (i.e., 1/3 of the RSUs and options will vest on each anniversary of the grant date, being on December 22 of each relevant year).

Includes 13,600 tenure-based options and RSUs (8,675 RSUs and 4,925 options) were granted to Jan Stern Reed and James Corbett as an initial grant in connection with their appointment to the Board of Directors.

2022 Annual Meeting Awards

Awards to the CEO under the 2022 Annual Meeting Awards

On December 12, 2022, the CEO was issued an aggregate 226,296 options with 25% of those options vesting annually commencing on September 28, 2023.

Non-Executive Director awards under the 2022 Annual Meeting Awards

The ~~tax benefits recognized in~~Director awards consist of an aggregate 71,936 options and RSUs (21,580 options and 50,356 RSUs) vesting 12 months from the ~~condensed consolidated financial statements related~~grant date.

•

17,984 tenure-based options and RSUs (12,589 RSUs and 5,359 options) granted to ~~a particular tax position are measured~~each of the four non-executive board members based on the ~~largest benefit that has~~vesting terms detailed above.

2023 Annual Meeting Awards

Awards to the CEO under the 2023 Annual Meeting Awards

On June 6, 2023, the CEO was issued an aggregate 100,000 options with 33.3% of those options vesting annually commencing on June 6, 2024.

Non-Executive Director awards under the 2023 Annual Meeting Awards

The Director awards consist of an aggregate 82,566 options and RSUs as follows:

•

52,926 tenure-based options and RSUs (15,876 options and 37,050 RSUs) vesting 12 months from the grant date.

8,821 tenure-based options and RSUs (2,646 options and 6,175 RSUs) granted to each of the six non-executive board members based on the vesting terms detailed above.

•

29,640 tenure-based options and RSUs (8,892 options and 20,748 RSUs) vesting on the first, second, and third anniversary of the grant date in equal amounts (i.e 1/3 of the options and RSUs will vest on each anniversary of the grant date, being June 6 of each relevant year)

14,820 tenure-based options and RSUs (4,446 options and 10,374 RSUs) granted to Cary Vance and Robert McNamara as an initial grant in connection with their appointment to the Board of Directors.

Employee Stock Purchase Plan

In June 2023, the stockholders approved the AVITA Medical, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP became effective on July 1, 2023. On June 30, 2023, the Company filed Registration Statement on Form S-8 to register 1,000,000 shares of common stock under the ESPP, as a ~~greater than~~result of the Company’s stockholders approving the ESPP at the 2023 Annual Meeting. The ESPP is implemented by a ~~50% likelihood~~series of ~~being realized upon settlement.~~offering periods, each of which is six months in duration, with new offering periods commencing on the first trading date of June and December of each year. The ~~amount~~first offering period for the ESPP is July 3 – November 30, 2023. Subsequent offering periods will be the first trading day of ~~unrecognized tax benefits is adjusted as appropriate for changes in facts~~November to the last trading day of May and ~~circumstances, such as significant amendments~~the first trading date of June to ~~existing tax law, new regulations or interpretations~~the last trading day of December.

The ESPP provides eligible employees with an opportunity to purchase shares of the Company’s common stock through payroll deductions of up to 15% of their eligible compensation. A participant may purchase a maximum of 5,000 shares of common stock during an offering period. Amounts deducted and accumulated by the ~~taxing authorities, new information obtained during a tax examination, or resolution~~participant are used to purchase shares of ~~an examination.~~common stock at the end of each six-month purchase period. The purchase price of the shares is 85% of the lower of the fair market value of the common stock on (i) the first trading day of the applicable offering period and (ii) the last trading day of each purchase period in the related offering period.

~~The Company has~~

Participants may withdraw from the offering at least 21 days before the purchase date. Accrued contributions that have not ~~identified any uncertain tax positions as~~yet been used to purchase shares of ~~September~~common stock will be repaid to the participant. Termination of employment at least 30 ~~2020 or~~days prior to the purchase date results in withdrawal from the offering and contributions are returned to the participant. If termination of employment occurs within 30 days of the purchase date, contributions are used to purchase shares on the purchase date.

Employee payroll contributions ultimately used to purchase shares are reclassified to stockholders’ equity on the purchase date. As of June 30, ~~2020.~~

~~On March 27, 2020,~~2023 and December 31, 2022, the ~~Coronavirus Aid, Relief, and Economic Security Act (“~~~~CARES Ac~~t”) was enacted in the United States. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses and technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property. The Company ~~evaluated the provisions of the CARES Act and~~ does not ~~anticipate~~have any accrued payroll contributions.

15. Income Taxes

Tax expense for the ~~associated impacts, if any, will have a material effect on its financial position.~~three-months ended June 30, 2023 and 2022 was $13,000 and $4,000, respectively, and $43,000 and $8,000 for the six-months ended June 30, 2023 and 2022, respectively. These amounts are related to state minimum taxes.

~~15.~~16. Net Loss per Share

The following is a reconciliation of the basic and diluted loss per share computations:

   Three Months Ended September 30,
   2020    2019
   (in thousands, expect per share data)
Net Loss
   $ 10,227    $ 3,566
Weighted-average common shares - outstanding, basic
   21,504    18,720
Weighted-average common shares - outstanding, diluted
   21,504    18,720




Net loss per common share, basic
   $ 0.48    $ 0.19




Net loss per common share, diluted
   $ 0.48    $ 0.19


	Three-Months Ended				Six-Months Ended
	June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
(in thousands, except per share amounts)
Net Loss	$	10,384	$	6,261	$	19,604	$	15,724
Weighted-average common shares—outstanding, basic and diluted		25,240		24,971		25,221		24,955
Net loss per common share, basic and diluted	$	0.41	$	0.25	$	0.78	$	0.63


	Three-Months Ended				Six-Months Ended
	June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Anti-dilutive shares excluded from diluted net loss per common share:
Stock options		2,675,458		1,774,070		2,675,458		1,774,070
Restricted stock units		378,541		220,920		378,541		220,920

The Company’s basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the relevant period. In accordance with ASC 710-10, 105,577 shares of common stock held by the rabbi trust are excluded from the denominator in the basic and diluted net loss per common share calculations. For details on shares of common stock held by the rabbi trust refer to Note 17. For the purposes of the calculation of diluted net loss per share, options to purchase common stock, restricted stock units and unvested shares of common stock issued upon the early exercise of stock options have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive. Because the Company has reported a net loss for the ~~three months~~three-months and six-months ended ~~September~~June 30, ~~2020~~2023, and ~~2019,~~2022, diluted net loss per common share is the same as the basic net loss per share for those periods.

The loss per share incorporates the impact of the reverse stock split that was effectuated in conjunction with the Redomicilation. In accordance with ASC 260, the impact of the reverse stock split was retrospectively applied for all periods presented.

~~16.~~17. Retirement Plans

The Company offers a 401(k)~~-retirement~~ retirement savings plan (the ~~“401(k)~~“401(k) Plan”) for its employees, including its executive officers, who satisfy certain eligibility requirements. The Internal Revenue Code of 1986, as amended, allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) Plan. The Company matches contributions to the 401(k) Plan based on the amount of salary deferral contributions the participant makes to the 401(k) Plan. The Company will match up to 6%6% of an employee’s compensation that the employee contributes to his or her 401(k) Plan ~~account.~~account up to the maximum allowable. Total ~~Company~~Company's matching contributions to the 401(k) Plan were ~~$165,000~~$249,000 and ~~$154,000~~$239,000 for the three-months ended June 30, 2023 and 2022, respectively, and $671,000 and $471,000 for the six-months ended June 30, 2023 and 2022, respectively.

Non-Qualified Deferred Compensation Plan

The Company’s NQDC plan, which became effective on October 2021, allows for eligible management and highly compensated key employees to elect to defer a portion of their salary, bonus and RSU awards to later years. Cash deferrals are immediately vested and are subject to investment risk, and a risk of forfeiture under certain circumstances. RSU deferrals are subject to the vesting conditions of the award. Once RSUs vest, subject to a six-month and one day holding period, employees are allowed to diversify the common stock into other investment options offered by the plan. For cash deferrals, the Company matches 4% to 6% (depending on level) of employee contributions. These matching employer contributions are vested over a two-year period with 25% vesting on year one and 75% vesting on year two for employees under 55 years of age. Employer contributions for employees over 55 years of age are immediately vested. Employer contributions to the NQDC plan were $39,000 and $38,000 for the three-months ended June 30, 2023 and 2022, respectively, and $80,000 and $122,000 for the six-months ended June 30, 2023 and 2022, respectively. The Company’s deferred compensation plan liability was $3.8 million and $1.3 million as of June 30, 2023 and December 31, 2022, respectively. These amounts are split between current and long term on the Consolidated Balance Sheets. As of June 30, 2023, $2.6 million is included in Current non-qualified deferred compensation liability and $1.2 million in Non-qualified deferred compensation liability. As of December 31, 2022, $78,000 is included in Current non-qualified deferred compensation liability and $1.3 million in Non-qualified deferred compensation liability. During the second quarter of 2023, the Company had a payout of approximately $82,000 in the ~~three months ended September~~deferred compensation liability for a terminated employee.

The fair values of the Company’s deferred compensation plan assets and liability are included in the table below. For additional information on the fair value hierarchy and the inputs used to measure fair value, see Note 4, Fair Value Measurements.


	Fair Value as of June 30, 2023								Fair Value as of December 31, 2022
(in thousands)	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Corporate-owned life insurance policies (1)	$	-	$	2,091	$	-	$	2,091	$	-	$	1,238	$	-	$	1,238
Non-qualified deferred compensation plan liability (2)		-		3,796		-		3,796		-		1,348		-		1,348

(1)

The corporate-owned life insurance contracts are recorded at cash surrender value, which is provided by a third party and reflects the net asset value of the underlying publicly traded mutual funds and are categorized as Level 2.

(2)

Non-qualified deferred compensation plan liability is measured at fair value based on quoted prices of identical instruments to the investment vehicles selected by the participants.

Rabbi Trust

During April 2022, the Company established a rabbi trust to hold the assets of the NQDC plan. The rabbi trust holds the COLI asset and the common stock from deferred RSU awards that have vested. The NQDC permits diversification of fully vested shares into other equity securities subject to a six-month and one day holding period. In accordance with ASR 268,Redeemable Preferred Stock, and ASC 718,Compensation — Stock Compensation, prior to vesting, the deferred share awards are classified as an equity instrument and changes in fair value of the amount owed to the participant are not recognized. The redemption amounts of the deferred awards are based on the vested percentage and are recorded outside of permanent equity as Non-qualified deferred

compensation share awards on the Consolidated Balance Sheets. As of June 30, ~~2020~~2023, a total of 165,399 shares awards have been deferred, and ~~2019, respectively.~~a total of 105,577 shares were vested at the redemption value of $892,000. As of December 31, 2022, a total of 253,048 share awards have been deferred, and a total of 17,927 awards vested with a redemption value of $127,000. Vested shares are converted to common stock and are reclassified to permanent equity. Common stock held in the rabbi trust is classified in a manner similar to treasury stock and presented separately on the Consolidated Balance Sheets as Common stock held by the NQDC plan.

~~17.~~

The following table summarizes the eligible share award activity as of June 30, 2023 and December 31, 2022 (in thousands):


		As of
(in thousands)		June 30, 2023			December 31, 2022
Non-qualified deferred compensation share awards:
Balance at inception/beginning of period		$	557		$	-
Change in classification of deferred compensation share awards			-			192
Stock-based compensation expense			411			471
Change in redemption value			1,025			21
Vesting of share awards held by NDQC			(765	)		(127	)
Ending Balance	��	$	1,228		$	557

18. Subsequent Events

The Company has ~~considered all~~evaluated subsequent events ~~occurring subsequent to September 30, 2020~~through the filing of this Quarterly Report on Form 10-Q and ~~has concluded~~determined that ~~all significant events~~there have been ~~disclosed~~no events that have occurred that would require adjustments to our disclosures in the ~~condensed consolidated financial statements~~Consolidated Financial Statements.

Item 2. Management’s Discussion and ~~accompanying notes.~~

Analysis of Financial Condition and Results of Operations

~~Item 2.~~

~~Management’s Discussion and Analysis of Financial Condition and Results of Operations~~

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited ~~condensed consolidated financial statements~~Consolidated Financial Statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q.

Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods.

The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under Part II, Item 1A. Risk Factors.

We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC and the ASX, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

~~Overview~~

~~The AVITA group of companies (comprising AVITA Therapeutics, Inc. (“~~~~AVITA Therapeutics~~~~” or the “~~~~Company~~~~”) and its subsidiaries, including~~ Please see “Special Statement Regarding Forward-Looking Statements” on page 3.

Overview

AVITA Medical, ~~Limited (“~~~~AVITA Medical~~~~”)) (collectively, “~~~~AVITA Group~~~~” or “~~Inc. ("we”", “us”"our", ~~or “~~~~our~~”"us")is a regenerative medicine ~~group with a technology platform positioned to address unmet medical needs in burn injuries, trauma~~company leading the development and ~~other acute injuries, together with~~commercialization of devices and autologous cellular therapies for skin ~~defects like vitiligo.~~restoration. Our patented and proprietary RECELL® System technology platform ~~technology provides innovative treatment solutions derived from~~harnesses the regenerative properties of a patient’s own ~~skin. Our medical device works by preparing~~ skin to create Spray-On Skin™Cells, an autologous ~~cellular~~skin cell suspension ~~comprised of~~that is sprayed onto the ~~patient’s skin cells, which is then sprayed on the~~ patient ~~in order~~ to regenerate natural healthy ~~epidermis.~~skin.

Our ~~first United States (“~~~~U.S.~~~~”) product,~~objective is to become the ~~RECELL~~^® ~~System, was approved by the U.S. Food and Drug Administration (“~~~~FDA~~”)leading provider of regenerative medicine addressing unmet medical needs in ~~September 2018 for the treatment of acute thermal~~ burn injuries, full-thickness skin defects, and in ~~patients 18 years and older. The RECELL System is used to prepare~~ ~~Spray-On~~ ~~Skin Cells using a small amount of a patient’s own~~ skin ~~providing a new way to treat severe burns, and simultaneously significantly reducing~~repigmentation, such as vitiligo. To achieve this objective, we plan to:

•

Become the amount of donor skin required. The RECELL System is designed to be used at the point of care as a standalone product, or in combination with “skin transplants”, known as split-thickness skin autografts, depending on the depth of the burn injury. The pivotal studies leading to the RECELL System’s FDA premarket approval (“~~PMA~~”) for the treatment of acute thermal burns, demonstrated that the RECELL System treated burns using 97.5 percent less donor skin when used alone in second-degree burns, and 32 percent less donor skin when used with autograft for third-degree burns compared to standard of care ~~autografting. In these studies, a statistically significant reduction~~ in ~~donor skin required to treat burn patients with~~ the U.S. burns industry by increasing RECELL System ~~was realized without any associated compromise to healing or safety outcomes. Donor site outcomes from the clinical trial for second-degree burns also revealed a statistically significant reduction~~penetration in ~~patient-reported pain, increased patient satisfaction and improved scar outcomes.~~

~~Our compelling data from prospective, randomized, controlled clinical trials conducted at major United States~~ burn centers ~~health economics modeling,~~ and ~~real-world use globally, demonstrate that the RECELL System is a significant advancement over the current standard of care for~~with burn ~~patients and offers benefits in clinical outcomes and cost savings.~~

~~Following receipt of our PMA, we commenced commercializing~~physicians

•

Continue to commercialize the RECELL System in ~~January 2019 in the U.S., and we expect the dominant focus of our commercial efforts to be directed towards~~ the U.S. ~~market going forward.~~

~~The RECELL System is Therapeutic Goods Administration (“~~~~TGA~~~~”)-registered in Australia cleared~~ for ~~use in the~~ treatment of ~~burns, acute wounds, scars~~full-thickness skin defects with both inpatient and outpatient reimbursement in place

•

Conduct a post-market study to demonstrate both the repigmentation ~~(vitiligo). In Europe, the RECELL System received~~ ~~CE-mark~~ ~~approval for the~~and mental health benefits after treatment of ~~burns, chronic wounds, scars~~stable vitiligo lesions using RECELL

•

Launch RECELL GO following FDA approval to increase market adoption, expand our customer base, and ~~vitiligo. Presently, we are not actively marketing the RECELL System internationally and therefore do not derive meaningful revenue from~~facilitate international commercialization

•

Commercialize the RECELL System in the U.S. for treatment of vitiligo lesions following the expected receipt of in-office reimbursement for the use of RECELL in the physician office setting, which we anticipate in 2025

•

Further invest in our RECELL System platform to automate and improve workflow, speed, and ease of use as it relates to specific indications, as well as to build upon our intellectual property estate

•

Continue to build upon commercial activities in Japan through our partnership with COSMOTEC Company, Ltd with our current PMDA approval for RECELL with an indication in burns

•

Develop and pursue viable commercial activities outside of the U.S. and Japan following the FDA approvals of the RECELL System for full-thickness skin defects and vitiligo

•

Pursue business development opportunities that are complementary to our core RECELL System indications and/or our targeted markets

•

Improve our margins and profitability by leveraging our current team and infrastructure across an expanding base of business in burns and in future indications

Business Environment and Current Trends

There remains significant uncertainty in the current macroeconomic environment due to factors including supply chain shortages, increased cost of healthcare, increased inflation rates, a competitive and tight labor market, and other related global economic conditions and geopolitical conditions. Additionally, there have been various economic indicators that the United States economy may be entering a recession in upcoming quarters. If these ~~markets.~~

~~Our website address is www.avitamedical.com. Information contained~~conditions continue or worsen, they could adversely impact our future operating results. An economic recession could potentially impact the general business environment and the capital markets, which may have a material negative impact on our ~~website is~~financial results.

Changes in reimbursement rates by third party payors may place additional financial pressure on hospitals and the broader healthcare system. Healthcare institutions may take actions to mitigate any persistent pressures on their budgets and such actions could impact the future demand for our products. Geopolitical conditions may also impact our operations. Although we do not ~~part~~have operations in Russia or Ukraine, the continuation of the Russia-Ukraine military conflict and/or ~~incorporated into~~an escalation of the conflict beyond its current scope may further weaken the global economy and could result in additional inflationary pressures and supply chain constraints.

Recent Developments

On June 7, 2023, the FDA approved a PMA supplement for full-thickness skin defects based on results of our trial for soft tissue repair and reconstruction. Following this ~~report.~~approval, we commenced a commercial launch on June 8, 2023.

On June 16, 2023, the FDA approved a PMA application for the repigmentation of stable depigmented vitiligo lesions. We ~~make~~plan to commence a full commercial launch following the expected receipt of in-office reimbursement for the use of RECELL in the physician office setting, which we anticipate in 2025.

On June 29, 2023, we submitted a PMA supplement to the FDA for our ~~periodic reports, together~~automated cell disaggregation device, RECELL GO™. RECELL GO maintains the FDA Breakthrough Device designation from predecessor devices. Under the Breakthrough Device program, the submission will receive prioritized, interactive review with ~~any amendments, available on our website, free of charge,~~approval expected by December 29, 2023.

Corporate History

The Company began as ~~soon as reasonably~~

~~practicable after we electronically file or furnish the reports with the Securities and Exchange Commission (“~~~~SEC~~~~”) or with~~a laboratory spin-off in the Australian ~~Securities Exchange (“~~~~ASX~~~~”).~~State of Western Australia. The SEC maintains an internet site, www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Copies of announcements made by the Company to the ASX are available on ASX’s website (www.asx.com.au).

~~Corporate History~~

~~AVITA Therapeutics, a Delaware corporation, was originally formed in April 2020. The~~Company's former parent company, ~~of the AVITA Group, AVITA Medical,~~Clinical Cell Culture (“C3”), was formed under the laws of the Commonwealth of Australia in December of 1992 and ~~has operated as~~changed its name to AVITA Medical ~~since 2008.~~ Ltd in 2008 ("AVITA ~~Medical’s~~Australia"). AVITA Australia’s ordinary shares originally began trading in Australia on the Australian Securities Exchange (“ASX”) on August 9, 1993. AVITA ~~Medical’s ordinary shares, in the form of~~Australia's American Depositary Shares (“ADSs”), traded over the counter on the OTCQX under the ticker symbol “AVMXY” from May 14, 2012, through September 30, 2019, and its ADSs began trading on ~~the NASDAQ Stock Market LLC (“~~~~NASDAQ~~”)Nasdaq on October 1, 2019, under the ticker symbol ~~“RCEL”.~~“RCEL.”

~~With effect from~~

On June 29, 2020, AVITA Australia implemented a statutory scheme of arrangement ~~was implemented~~ under Australian law to ~~change the domicile~~effect a redomiciliation of ~~the~~ AVITA ~~Group~~Medical from Australia to the ~~U.S. Under~~United States (the “Redomiciliation”). The Redomiciliation was approved by stockholders on June 15, 2020 and approved by the ~~scheme~~Federal Court of ~~arrangement, AVITA Therapeutics, being a company incorporated in~~Australia on June 22, 2020. Pursuant to the ~~State of Delaware in the U.S., became the new parent company of the AVITA Group, and~~Redomiciliation, all ordinary shares in AVITA ~~Medical (including ordinary shares represented by ADSs) held by securityholders~~Australia were exchanged for shares of common stock ~~or CHESS Depositary Interests (“~~~~CDIs~~”in the Company (AVITA Medical, Inc.). As a result, the ~~existing listing~~Company became the sole stockholder of AVITA ~~Medical~~Australia.

The Company’s CHESS Depositary Interests (“CDIs”) are quoted on the ASX ~~(as its primary listing) and on NASDAQ (as its secondary listing) was inverted and replaced with a new listing of~~under AVITA ~~Therapeutics on NASDAQ (as its primary listing) under the existing~~Australia’s former ASX ticker ~~symbol, “RCEL”, and on the ASX (as its secondary listing) under the existing ticker symbol,~~code, “AVH”. ~~AVITA Therapeutics’~~The Company’s shares of common stock ~~trade~~are quoted on ~~NASDAQ and its CDIs trade on ASX (with five CDIs trading on ASX representing one~~Nasdaq under AVITA Australia's former Nasdaq ticker code, “RCEL.” One share of common stock on ~~NASDAQ).~~

~~COVID-19~~ ~~Business Update~~

~~The global~~ ~~COVID-19~~ ~~pandemic presents significant risks~~Nasdaq is equivalent to us and may have far reaching impacts on our business, operations, and financial results and condition, directly and indirectly, including, without limitation, impacts on: the health of our management and employees; manufacturing, distribution, marketing and sales operations; research and development activities, including clinical activities; and customer and patient behaviors.

~~Beginning in March 2020, the~~ ~~COVID-19~~ ~~pandemic began impacting our operations and financial results. For example, on March 19, 2020, the Executive Department of the State of California issued Executive Order~~ ~~N-33-20,~~ ordering all individuals in the State of California to stay at home or at their place of residence except as needed to maintain continuity of operations of federal critical infrastructure sectors. Our primary operations are located in Santa Clarita and Ventura, California. We have taken a variety of steps to address the impact of the ~~COVID-19~~ pandemic, while attempting to minimize business disruption. Essential staff in manufacturing and limited support functions have continued to work from our locations following appropriate hygiene and social distancing protocols. To reduce the risk to our employees and their families from potential exposure to ~~COVID-19,~~ ~~all other staff have been required to work from home (excluding our field force). We have restricted~~ ~~non-essential~~ ~~travel to protect the health and safety of our employees and customers.~~

Moreover, beginning in March 2020, access to hospitals and other customer sites was restricted to essential personnel, which has negatively impacted our ability to promote the use of the RECELL System with physicians, and to enroll our clinical studies. In addition, some hospitals and other burn centers suspended the treatment of burn patients or ~~re-distributed~~ those patients to other treatment facilities and, together with a general reduction in broader economic activity (e.g. reduced travel, reduced mobility, suspension of certain business operations, etc.), this resulted in a significant reduction in the volume of burn procedures using the RECELL System in the immediate period following the implementation of those protective measures. We are continuing to monitor the impact of the ~~COVID-19~~ ~~pandemic on our employees and customers and~~five CDIs on the ~~markets in which~~ASX.

On November 8, 2021, the Company changed its fiscal year-end from June 30th to December 31st. The decision to change the fiscal year-end to a calendar year end was to align our reporting cycle more closely with how we ~~operate, and will take further actions that we consider prudent to address the~~ ~~COVID-19~~ ~~pandemic, including reducing spending, while ensuring that we can support~~manage our ~~customers and continue to develop our products. The ultimate extent of the impact of the~~ ~~COVID-19~~ pandemic on us remains highly uncertain and will depend on future developments and factors that continue to evolve, most of which are outside of our control, and could exist for an extended period of time even after the pandemic might end. Quarantines, ~~shelter-in-place~~ and similar government orders have also impacted and may continue to impact, our third-party manufacturers and suppliers, and could in turn adversely impact the availability or cost of materials, which could disrupt our supply chain.

business.

Results of Operations for the three-months ended June 30, 2023 compared to the three-months ended June 30, 2022.

The table below summarizes the results of our ~~continuing~~ operations for each of the periods ~~presented.~~presented (in thousands).


	Three months ended September 30,												Three-Months Ended						$			%
	2020			2019			$ Change			% Change
Statement of Operations Data:													June 30, 2023			June 30, 2022			Change			Change
Revenues	$	5,060		$	3,250		$	1,810			56	%	$	11,753		$	8,335			3,418			41	%
Cost of sales		929			619			310			50	%		(2,204	)		(1,386	)		(818	)		(59	)%

Gross profit		4,131			2,631			1,500			57	%		9,549			6,949			2,600			37	%

BARDA income		596			2,051			(1,455	)		-71	%		530			551			(21	)		(4	)%
Operating expenses:
Operating Expenses:
Sales and marketing expenses		2,935			2,962			(27	)		-1	%		(10,003	)		(5,332	)		(4,671	)		(88	)%
General and administrative expenses		5,536			3,071			2,465			80	%		(6,165	)		(5,471	)		(694	)		(13	)%
Research and development expenses		3,204			1,635			1,569			96	%		(5,076	)		(3,059	)		(2,017	)		(66	)%
Share-based compensation		3,266			672			2,594			386	%

Total operating expenses		14,941			8,340			6,601			79	%		(21,244	)		(13,862	)		(7,382	)		(53	)%

Operating loss		(10,214	)		(3,658	)		(6,556	)		179	%		(11,165	)		(6,362	)		(4,803	)		(75	)%
Interest expense		7			11			(4	)		-36	%		(7	)		(4	)		(3	)		(75	)%
Other income		4			103			(99	)		-96	%		801			109			692			635	%

Loss before income taxes		(10,217	)		(3,566	)		(6,651	)		187	%		(10,371	)		(6,257	)		(4,114	)		(66	)%
Income tax expense		10			—			10			100	%		(13	)		(4	)		(9	)		(225	)%

Net loss	$	(10,227	)	$	(3,566	)	$	(6,661	)		187	%	$	(10,384	)	$	(6,261	)		(4,123	)		(66	)%

~~Three months ended September 30, 2020~~

Total net revenues increased by 41%, or $3.4 million, to $11.8 million, compared to ~~three months~~$8.3 million in the corresponding period in the prior year. Our commercial revenue, which excludes BARDA revenue, was $11.7 million in the three-months ended ~~September~~June 30, ~~2019~~

~~Revenue of the RECELL System totaled $5.1 million for the three months ended September 30, 2020,~~2023, an increase of ~~$1.8~~$3.4 million, or ~~56% over~~42%, compared to $8.2 million in the ~~$3.3~~corresponding period in the prior year. The growth in commercial revenues was largely driven by deeper penetration within individual customer accounts along with the commencement of commercial sales with our partner COSMOTEC in Japan.

Gross profit margin was 81% compared to 83% in the corresponding period in the prior year. The decrease was largely driven by lower production in one month of the quarter caused by the need to qualify new vendors for certain manufacturing components. However, throughout the process of strengthening our supply chain we maintained our perfect service level.

BARDA income decreased 4% or $21 thousand to $0.5 million, ~~reported for~~compared to $0.6 million in the ~~three months ended September 30, 2019. Consistent with~~corresponding period in the prior year the current quarter increase in sales occurred in the United States as a result of the September 2018 FDA approval and commencement of the U.S. national market launch of the RECELL System in January 2019. Gross margin for the three months ended September 30, 2020 was 82% compareddue to ~~81% for the same period in 2019.~~

reimbursable clinical trials winding down. BARDA income consisted of funding from the Biomedical Advanced Research and Development Authority, (“~~BARDA~~~~”),~~ under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. ~~Under~~

Total operating expenses increased by 53% or $7.4 million to $21.2 million, compared with $13.9 million in the ~~BARDA grant, income of $596,000 was recognized during~~corresponding period in the three months ended September 30, 2020 compared to income of $2.1 million for the three months ended September 30, 2019. BARDA arrangement declined as a result of wind-down of certain activities associated with supporting the U.S. FDA approval of the RECELL System as well as the compassionate use and continued access programs.prior year.

~~Operating costs for the year ended September 30, 2020 totaled $14.9 million, a $6.6 million or 79% increase over the $8.3 million incurred during the three months ended September 30, 2019.~~

Sales and marketing expenses ~~for the three months ended September 30, 2020 totaled $2.9~~increased by 88%, or $4.7 million, ~~and were flat~~to $10.0 million, compared to $5.3 million in the ~~three months ended September 30, 2019.~~ corresponding period in the prior year. Higher costs in the current year were primarily related to higher salaries and benefits and commissions. The increase in salaries and benefits is due to the preparation of the commercial launch of Full Thickness Skin Defect Launch ("FTSD") that occurred in June 2023. Higher commissions were directly associated with the increase in revenues.

General and administrative expenses ~~totaled~~increased by 13%, or $0.7 million, to $6.2 million, compared to $5.5 million ~~for~~in the ~~three months ended September 30, 2020, an increase of $2.5 million or 80% over~~same period in the ~~$3.1 million recognized during the three months ended September 30, 2019.~~prior year. The increase was attributable to deferred compensation expense and professional fees, partially offset by lower stock-based compensation. The increase in deferred compensation expense is driven by our deferred compensation liability, which generally tracks the ~~Company’s status as a cross listed entity on NASDAQ and~~movements in the ~~ASX,~~ ~~one-time~~stock market. Higher professional ~~services costs associated with establishing~~fees were primarily due to the ~~Company as a domestic filer with~~timing of our annual general meeting in the ~~SEC following completion~~current year. Lower stock-based compensation in the current period is due to the termination of two former executive officers during Q1 2023, which resulted in an acceleration of the ~~Redomiciliation, and severance costs associated with a former executive employee.~~ expense in Q1 2023.

Research and development expenses increased by 66%, or $2.0 million, to $5.1 million, compared to $3.1 million in the same period in the prior year. The increase is due to the development of the next generation RECELL GO for preparation of Spray-On Skin Cells, which resulted in a PMA submission in June 2023, and additional costs associated with the deployment of a team of Medical Science Liaisons, for the ~~three months~~FTSD launch in June 2023. The increase was partially offset by lower clinical trial expenses for vitiligo, FTSD and pediatrics as trial participants largely completed follow-up in 2022 reducing the associated expenditure in the current period.

Results of Operations for the six-months ended ~~September~~June 30, ~~2020 totaled $3.2~~2023 compared to the six-months ended June 30, 2022.

The table below summarizes the results of our operations for each of the periods presented (in thousands).


	Six-Months Ended						$			%
Statement of Operations Data:	June 30, 2023			June 30, 2022			Change			Change
Revenues	$	22,303		$	15,874			6,429			41	%
Cost of sales		(3,871	)		(3,164	)		(707	)		(22	)%
Gross profit		18,432			12,710			5,722			45	%
BARDA income		1,157			1,285			(128	)		(10	)%
Operating Expenses:
Sales and marketing expenses		(16,543	)		(10,160	)		(6,383	)		(63	)%
General and administrative expenses		(14,460	)		(13,005	)		(1,455	)		(11	)%
Research and development expenses		(9,662	)		(6,679	)		(2,983	)		(45	)%
Total operating expenses		(40,665	)		(29,844	)		(10,821	)		(36	)%
Operating loss		(21,076	)		(15,849	)		(5,227	)		(33	)%
Interest expense		(11	)		(4	)		(7	)		(175	)%
Other income		1,526			137			1,389			1014	%
Loss before income taxes		(19,561	)		(15,716	)		(3,845	)		(24	)%
Income tax expense		(43	)		(8	)		(35	)		(438	)%
Net loss	$	(19,604	)	$	(15,724	)		(3,880	)		(25	)%

Total net revenues increased by 41%, or $6.4 million, to $22.3 million, compared to $15.9 million in the corresponding period in the prior year. Our commercial revenue, which excludes BARDA revenue, was $22.1 million in the six-months ended June 30, 2023, an increase of ~~$1.6~~$6.4 million, or ~~96% over~~43%, compared to $15.7 million in the ~~$1.6 million recognized during~~corresponding period in the ~~three months ended September 30, 2019.~~prior year. The growth in commercial revenues was largely driven by deeper penetration within individual customer accounts along with the commencement of commercial sales with our partner COSMOTEC in Japan.

Gross profit margin increased by 3% to 83% compared to 80% in the corresponding period in the prior year. The increase ~~was~~in gross profit margin is largely driven by higher production along with lower shipping costs.

BARDA income decreased 10% or $0.1 million to $1.2 million, compared to $1.3 million in the corresponding period in the prior year due to reimbursable clinical trials winding down.

Total operating expenses increased by 36% or $10.8 million to $40.7 million, compared with $29.8 million in the corresponding period in the prior year.

Sales and marketing expenses increased by 63%, or $6.4 million, to $16.5 million, compared to $10.2 million incurred in the corresponding period in the prior year. Higher costs in the current year were primarily attributed to ~~the commencement of pivotal trials for treatment of pediatric scald injuries, soft tissue reconstruction, treatment of vitiligo~~higher salaries and ~~other research~~benefits, commissions, recruitment fees and development activities to further promote the RECELL device. Share based compensation also increased to $3.2 million for the three months ended September 30, 2020, an increase of $2.5 million or 386% over the $672,000 recognized during the three months ended September 30, 2019.travel costs. The increase ~~was primarily driven by an increase~~ in ~~awards granted along~~salaries and benefits and recruitment fees are due to the preparation of the commercial launch of FTSD in June 2023. Higher commissions and travel costs were directly associated with the increase in ~~grant fair value.~~revenues.

General and administrative expenses increased by 11%, or $1.5 million, to $14.5 million, compared to $13.0 million incurred in the same period in the prior year. The increase was attributable to deferred compensation expense, professional fees, and severance costs, partially offset by lower stock-based compensation. The increase in deferred compensation expense is driven by our deferred compensation liability which generally tracks the ~~grant date fair value~~movements in the stock market. Higher professional fees were primarily due to the timing of our annual general meeting in the ~~awards~~current year. Severance costs in the current year were due to the termination of two former executive officers. Lower stock-based compensation in the current year is due to the ~~increase~~acceleration of expense for certain performance milestones being met in the ~~Company’s stock price compared to the~~ prior ~~year.~~

Net loss for the three months ended September 30, 2020 was $10.2 million, an increase of $6.6 million or 187% over the $3.6 million recognized during the three months ended September 30, 2019. The increase in net loss was driven by the higher operating costs described above,year, partially offset by the ~~higher revenue during~~current period acceleration related to the ~~three months ended September 30, 2020. As a result~~termination of two former executive officers in the current year.

Research and development expenses increased by 45%, or $3.0 million, to $9.7 million, compared to $6.7 million incurred in the same period in the prior year. The increase is due to the development of the ~~U.S. national~~next generation RECELL GO for preparation of Spray-On Skin Cells, which resulted in a PMA submission in June 2023, and additional costs associated with the deployment of a team of MSLs, for the FTSD launch ~~of the RECELL System~~ in ~~January 2019, and the expansion of research and development including multiple pivotal clinical studies seeking premarket approval from the FDA, operating expenses are expected to~~June 2023. The increase ~~in future periods. These expenses are expected to be~~was partially offset by ~~increased commercial sales of~~lower clinical trial expenses for vitiligo, soft tissue and pediatrics as trial participants largely completed follow-up in 2022 reducing the ~~RECELL System.~~associated expenditure in the current period.

Liquidity and Capital Resources

Overview

We expect to utilize cash reserves until U.S. sales of our products reach a level sufficient to fund ongoing operations. ~~The~~ AVITA ~~Group~~Medical has historically funded its research and development activities, and more recently its substantial investment in sales and marketing activities, through raising capital by issuing securities, and it is expected that similar funding will be obtained to provide working capital if and when required. As of June 30, 2023, the Company had approximately $37.5 million in cash and cash equivalents and $31.3 million in marketable securities and believes it has sufficient cash reserves to fund operations for the next 12-months. If the Company is unable to raise capital in the future, the Company may need to curtail expenditures by scaling back certain research and development or other programs.

Financing Activities

In March 1, 2021, the Company completed an underwritten offering of its common stock for gross proceeds of approximately $69.1 million. AVITA Medical also benefits from cash inflows from the BARDA contract. We entered into the contract on September 29, 2015, and the scope has expanded through a number of amendments to the contract. The current contract period continues to December 31, 2023, with the option by BARDA to terminate earlier. The contract provided funding for the development of the RECELL System. The contract will continue to provide funding for future use of the product as a medical countermeasure to assist disaster preparedness and response in the U.S. for mass casualty events involving burn injuries.

On April 14, 2023, the Company entered into a Sales Agreement with Cowen and Company, LLC pursuant to which the Company may sell from time-to-time up to 3,799,164 shares of its common stock (the “2023 ATM Program”). During the quarter ended June 30, 2023, the Company did not make any sales under the 2023 ATM Program.

Given the above, we believe there is presently sufficient working capital to support our committed research and development programs and other activities over the next twelve months.

The following table summarizes our cash flows for the periods ~~presented:~~presented (in thousands):

   Three Months Ended
September 30,
(In Thousands)
   2020    2019
Net cash used in operations
   $ (7,713 )    $ (4,881 )
Net cash used in investing activities
   (296 )    (152 )
Net cash used in financing activities
   (4 )    (17 )
Effect of foreign exchange rate on cash and restricted cash
   127    (22 )
Net decrease in cash and restricted cash
   (7,886 )    �� (5,072 )
Cash and restricted cash at beginning of the period
   73,840    20,374
Cash and restricted cash at end the period
   65,954    15,302



	Six-Months Ended
(In Thousands)	June 30, 2023			June 30, 2022
Net cash used in operations	$	(18,174	)	$	(12,877	)
Net cash provided/(used) in investing activities		37,150			(7,845	)
Net cash provided by financing activities		342			1
Effect of foreign exchange rate on cash and cash equivalents and restricted cash		3			(52	)
Net increase/(decrease) in cash and cash equivalents and restricted cash		19,321			(20,773	)
Cash and cash equivalents and restricted cash at beginning of the period		18,164			55,712
Cash and cash equivalents and restricted cash at end of the period		37,485			34,939

~~Three Months Ended September 30, 2020, and 2019~~

Net cash used in operating activities was ~~$7.7~~$18.2 million and ~~$4.9~~$12.9 million during the ~~three months~~six-months ended ~~September~~June 30, ~~2020~~2023, and ~~2019,~~2022, respectively. The increase in net cash used in operations was primarily due to higher operating costs, ~~associated with the Company’s status as a cross listed entity on NASDAQ~~partially offset by increased revenues.

Net cash provided by investing activities was $37.2 million and ~~the ASX, the commercialization of the RECELL System in the United States, and the expansion of research and development activities.~~

~~Net~~net cash used in investing ~~activities~~ was ~~$296,000 and $152,000~~$7.8 million during the ~~three months~~six-months ended ~~September~~June 30, ~~2020~~2023 and ~~2019,~~2022, respectively. ~~Cash flows used for~~The increase in cash provided by investing activities ~~was~~is primarily attributable to ~~payments for~~our maturities of marketable securities, whereas in the ~~purchase of a property and equipment.~~prior year we purchased marketable securities.

Net cash ~~used~~provided by financing activities was ~~$4,000~~$0.3 million and ~~$17,000 for~~$1 thousand during the ~~three months~~six-months ended ~~September~~June 30, ~~2020~~2023, and ~~2019, respectively, and~~2022, respectively. The increase in cash provided by financing activities is related to ~~principal repayment~~proceeds from the exercises of ~~finance lease.~~stock options.

Capital ~~management~~Management and Material Cash Requirements

We aim to manage capital so that the Company continues as a going concern while also maintaining optimal returns to stockholders and benefits for other stakeholders. We also aim to maintain a capital structure that ensures the lowest cost of capital available to the Company. We regularly review the Company’s capital structure and seek to take advantage of available opportunities to improve outcomes for the Company and its stockholders.

For the ~~three months~~six-months ended ~~September~~June 30, ~~2020,~~2023, there were no dividends paid and we have no plans to commence the payment of dividends. We have no purchase commitments or long-term contractual obligations or purchase commitments, except for lease obligations as of June 30, 2023. Refer to Note 6 of our Consolidated Financial Statements for further details on our lease obligations. In addition, we have no off-balance sheet arrangements (as defined in the rules and regulations of the SEC) that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. We have no committed plans to issue further shares on the market but will continue to assess market conditions and the Company’s cash flow requirements to ensure the Company is appropriately funded in order to pursue its various opportunities.

There is no significant external borrowing at the reporting date. Neither the Company nor any of the subsidiaries are subject to externally imposed capital requirement.

~~Item 3.~~

~~Quantitative and Qualitative Disclosures About Market Risk~~

Critical Accounting Estimates

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial ~~instruments, which subject us~~Condition and Results of Operations,” included in the Company’s Annual Report on Form 10-K for the year-ended December 31, 2022.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to ~~concentrations of credit risk, consist primarily of cash. We maintain cash in three financial institutions. We perform periodic evaluations of~~provide the ~~relative credit standing of these institutions.~~information required by this Item.

~~Item 4.~~

~~Controls and Procedures~~

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and our Chief Financial Officer evaluated, with the participation of our management, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. As of ~~September~~June 30, ~~2020,~~2023, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures, as defined in Securities Exchange Act Rule 13a-15(e) and 15d-15(e), were effective.

Our disclosure controls and procedures have been formulated to ensure (i) that information that we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934 ~~were~~was recorded, processed, summarized and reported within the time periods specified in ~~Securities and Exchange Commission~~the SEC’s rules and forms and (ii) that the information required to be disclosed by us is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Changes in Internal Controls over Financial Reporting

There was no change in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the ~~first~~second quarter of fiscal year ~~2021~~2023 covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. ~~We have not experienced any material impact to our internal controls over financial reporting despite the fact that many of our employees are working remotely due to the~~ ~~COVID-19~~ ~~pandemic. We are continually monitoring and assessing the~~ ~~COVID-19~~ ~~situation on our internal controls to minimize the impact on their design and operating effectiveness.~~

Part II - Other Information

~~Item 1.~~

~~LEGAL PROCEEDINGS~~

~~None.~~

~~Item 1A.~~

~~Risk Factors~~

~~None.~~Item 1. LEGAL PROCEEDINGS

~~Item 2.~~

~~UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS~~

~~None~~

~~Item 3.~~

~~DEFAULTS UPON SENIOR SECURITIES~~

~~None~~We are not currently a party to any pending legal proceedings that we believe will have a material adverse effect on our business or financial condition. We may, however, be subject to various claims and legal actions arising in the ordinary course of business from time to time.

~~Item 4.~~

~~MINE SAFETY DISCLOSURES~~

Item 1A. RISK FACTORS

In addition to the risk factor set forth below and the other information set forth in this report, you should carefully consider the factors discussed under Part I, Item 1A, “Risk Factors” in the Company’s Annual Report on Form 10-K for the year-ended December 31, 2022 (the “2022 Annual Report”) and as updated in the Company’s subsequent Quarterly Reports on Form 10-Q. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by the forward-looking statements contained in this report. Except as disclosed below, there have been no material changes to the risk factors described in Part I, Item 1A, “Risk Factors,” included in our 2022 Annual Report.

The Company's cash, cash equivalents and marketable securities could be adversely affected by bank failures or other events affecting financial institutions and could adversely affect our liquidity and financial performance.

We regularly maintain domestic cash deposits in Federal Deposit Insurance Corporation (“FDIC”) insured banks, which exceed the FDIC insurance limits. We also maintain cash deposits in foreign banks where we operate, some of which are not insured or are only partially insured by the FDIC or other similar agencies. The failure or rumored failure of a bank, or events involving limited liquidity, defaults, non-performance, bankruptcy, receivership or other adverse developments in the financial or credit markets impacting financial institutions, may lead to disruptions in access to our bank deposits. These disruptions may adversely impact our liquidity and financial performance. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the U.S. or applicable foreign government, or that any bank or financial institution with which we do business will be able to obtain needed liquidity from other banks, government institutions or by acquisition in the event of a failure or liquidity crisis. As such, those funds in bank deposit accounts in excess of the standard FDIC insurance limits are uninsured and subject to the risk of bank failure.

Currently, the Company has full access to all funds in deposit accounts or other money management arrangements. The failure of any bank in which the Company deposits its funds could reduce the amount of cash the Company has available for its operations or delay its ability to access such funds. In the event of such failure, the Company may experience delays or other issues in meeting its financial obligations, the Company’s ability to access its cash and cash equivalents may be threatened and could have a material adverse effect on the Company’s business and financial condition.

Future adverse developments with respect to specific financial institutions or the broader financial services industry may also lead to market-wide liquidity shortages.

Development and commercialization of our products require successful completion of the regulatory approval process and any delays or failures in obtaining regulatory approvals for improvements to or expanded indications for our current offerings, could prevent, delay or adversely impact commercialization of our products.

In the United States, as well as other jurisdictions, we have been and will be required to apply for and receive regulatory authorization before we can market our products. For instance, our RECELL System has been approved by the U.S. Food and Drug Administration and regulatory authorities in Australia, the EU and Japan for use in certain treatments of burns, acute wounds, scars and vitiligo. However, we will require additional clinical data or approvals from regulatory authorities within these countries to market the product for the treatment of other indications, and from any other jurisdictions in which we seek to market the product. This process can be time-consuming and complicated and may be unsuccessful or otherwise result in unanticipated delays or fail altogether. To secure marketing authorization, an applicant generally is required to submit an application that includes the data supporting preclinical and clinical safety and effectiveness as well as detailed information on the manufacturing and control of the product, proposed labeling and other additional information. Before marketing authorization is granted, regulatory authorities may require the inspection of the manufacturing facility or facilities and quality systems (including those of third parties) at which the product candidate is manufactured and tested, as well as potential audits of the non-clinical and clinical trial sites that generated the data cited in the marketing authorization application.

We cannot predict whether any additional marketing authorizations will ultimately be granted or how long the applicable regulatory authority or agency will take to do so. Regulatory agencies, including the FDA, have substantial discretion in the approval process. In addition, the approval process and the requirements governing clinical trials vary from country to country. The policies of the FDA or other regulatory authorities may change, and additional government regulations may be enacted that could prevent, limit or delay the necessary approval of any products we may develop and commercialize. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or elsewhere. If we are slow or unable to adapt to new or changed requirements, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.

Additionally, any future regulatory approvals that we receive may also contain requirements for costly post-marketing testing and surveillance to monitor the safety and effectiveness of the product. Once a product is approved, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export, and record keeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submission of safety and other post-marketing reports, registration, and continued compliance with good manufacturing practices for any clinical trials that we conduct post-approval.

Finally, per FDA regulations, changes made to products, specifications, or test data evaluation methodology would generally require communication with the FDA. There are several pathways for communicating with the FDA of such changes. As part of such review, the FDA may request additional information, at which time the product may become temporarily unavailable.

Certain of our products are dependent on specialized sources of supply potentially subject to disruption which could have a material, adverse impact on our business.

Although the COVID-19 pandemic has ended, supply chain disruptions, raw material shortages, and inflationary pressures may continue for the foreseeable future. Due to the cost and regulatory requirements associated with qualifying multiple suppliers, in the prior year we single-sourced some of our material components. To the extent that any of these single sourced suppliers experienced disruptions in deliveries due to production, quality, or other issues, we were potentially subject to similar production delays or unfavorable cost increases. In the current quarter, we invested resources in obtaining additional suppliers for some of our key raw materials. This resulted in a decrease in our gross margin, however, the Company is now in a better position to mitigate supply chain risk and manage operations and cash flow.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

~~Item 5.~~

~~OTHER INFORMATION~~

~~None~~

Item 5. OTHER INFORMATION

~~Item 6.~~

~~EXHIBITS~~

None

Item 6. EXHIBITS

(a) The following exhibits are filed as part of the Quarterly Report on Form 10-Q:


Exhibit No.		Description

~~31.1~~ 3.1		Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant’s Form 8-K12B filed on June 30, 2020)

3.2		Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.2 of the registrant’s Form 10-KT filed on February 28, 2022)

3.3		Amended and Restated Bylaws (incorporated by reference to Exhibit 3.3 of the registrant’s Form 10-KT filed on February 28, 2022)

10.1		Amendment No. 1 to the 2020 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed on June 7, 2023) †

10.2		AVITA Medical, Inc. Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 of the Registrant’s Form 8-K filed on June 7, 2023) †

10.3		Executive Employment Agreement between the registrant and David O'Toole dated June 17, 2023†*

31.1*		Rule 13a-14(a) Certification of Chief Executive Officer

~~31.2~~ 31.2*		Rule 13a-14(a) Certification of Chief Financial Officer

32 32**		18 U.S.C. Section 1350 Certifications

101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

† Management contract or compensation plan or arrangement

~~Signatures~~* Filed herewith

** Furnished herewith

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: ~~November~~	August 10, ~~2020~~			~~AVITA THERAPEUTICS, INC.~~

			~~By:~~	2023	~~/s/ Dr. Michael Perry~~	AVITA MEDICAL, INC.
					~~Dr. Michael Perry~~
		By:	/s/ James Corbett
			James Corbett
			President and Chief Executive Officer
					(Principal Executive Officer)

			~~By:~~		~~/s/ Sean Ekins~~
					~~Sean Ekins~~
		By:			~~VP of Finance~~ /s/ David O'Toole
			David O'Toole
			Chief Financial Officer
			(~~Interim~~ Principal Financial and Accounting Officer)

2541


	Three Months Ended September 30, 2020
	Common Stock
	Shares		Amount		Additional Paid-in- Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit			Total Shareholders’ Equity
Balance at June 30, 2020		21,467,912	$	3	$	259,165	$	8,146	$	(194,913	)	$	72,401

Net loss		—		—		—		—		(10,227	)		(10,227	)
Share-based compensation		—		—		3,266		—		—			3,266
Exercise of stock options		3,538		—		—		—		—			—
Vesting of restricted stock units		151,837		—		—		—		—			—
Translation gain		—		—		—		48		—			48

Balance at September 30, 2020		21,623,287	$	3	$	262,431	$	8,194	$	(205,140	)	$	65,488


	Three Months Ended September 30, 2019
	Common Stock
	Shares		Amount		Additional Paid-in- Capital		Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit			Total Shareholders’ Equity
Balance at June 30, 2019		18,712,996	$	3	$	165,473	$	8,184		$	(152,828	)	$	20,832

Net loss		—		—		—		—			(3,566	)		(3,566	)
Share-based compensation		—		—		672		—			—			672
Issuance of common stock to director in lieu of directors fees		15,853		—		107		—			—			107
Beginning balance adjustment related ot the adoption of ASC 842		—		—		—		—			(55	)		(55	)
Translation loss		—		—				(34	)		—			(34	)

Balance at September 30, 2019		18,728,849	$	3	$	166,252	$	8,150		$	(156,449	)	$	17,956


	Estimated Amortization Expense
Remainder of 2021	$	70
2022		67
2023		21
2024		21
2025		21
2026 and thereafter		173

Total	$	373

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company